Original Article
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
N Engl J Med 2010; 363:809-819August 26, 2010
- Abstract
Background
The identification of somatic mutations in the gene encoding the serine–threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.
Methods
We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the maximum dose that could be administered without adverse effects (the recommended phase 2 dose). Patients received PLX4032 twice daily until they had disease progression. Pharmacokinetic analysis and tumor-response assessments were conducted in all patients. In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.
Results
A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 additional patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase. The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia. In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response. Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response. The estimated median progression-free survival among all patients was more than 7 months.
Conclusions
Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients. (Funded by Plexxikon and Roche Pharmaceuticals.)
Media in This Article
Figure 1
Mean PLX4032 Concentrations over a 24-Hour Period.Figure 2
Representative Findings of the Effect of PLX4032 at the Recommended Phase 2 Dose in Study Patients with Melanoma That Carried the V600E Mutation.Article Activity
- Article
Metastatic melanoma is an aggressive disease for which there are few effective therapies. The two therapies approved by the Food and Drug Administration, high-dose interleukin-2 and dacarbazine, are each associated with response rates of only 10 to 20% and a small percentage of complete responses; neither is thought to improve overall survival.1,2 In randomized trials, the median survival among patients treated with dacarbazine was less than 8 months.3,4
A search for mutations in a component of the mitogen-activated protein (MAP) kinase pathway in a large panel of common cancers revealed that 40 to 60% of melanomas, and 7 to 8% of all cancers, carry an activating mutation in the gene encoding the serine–threonine protein kinase B-RAF (BRAF). 5-15 Ninety percent of reported BRAF mutations result in a substitution of glutamic acid for valine at amino acid 600 (the V600E mutation). This BRAF mutation constitutively activates BRAF and downstream signal transduction in the MAP kinase pathway. BRAF mutations are also found in 40 to 70% of papillary or anaplastic thyroid cancers6-8,16-18 and in a small percentage of several other types of tumor.
PLX4032 (Plexxikon; RG7204, Roche Pharmaceuticals) is a potent inhibitor of BRAF with the V600E mutation. Preclinical studies showed that PLX4032 and its analogue PLX4720 inhibit the kinase activity of BRAF with the V600E mutation at low nanomolar concentrations, abrogate signaling through the MAP kinase pathway, and block proliferation of cells carrying BRAF with the V600E mutation in vitro at high nanomolar concentrations.17,18 Orally administered PLX4720 inhibits the growth — and, at higher doses, induces the regression — of human melanoma tumors transplanted into immunocompromised mice. None of these effects are observed in normal tissues or in tumor cells that lack a BRAF mutation.
We conducted a trial of the use of PLX4032 in patients with metastatic cancer. The primary goals were to define the safety and pharmacokinetic characteristics of treatment with continuous, twice-daily administration of PLX4032, to determine the maximum dose that could be administered until adverse effects prevented further dose increases (i.e., the recommended phase 2 dose), and to determine the objective response rate, the duration of response, and the rate of progression among patients who had melanoma tumors with the V600E BRAF mutation and who were given the recommended phase 2 dose of PLX4032.
Methods
Study Design
The study was sponsored by Plexxikon and Roche Pharmaceuticals, which provided the study drug. The study was designed by two academic authors and one industry author. All authors made the decision to submit the manuscript for publication. All authors analyzed the data, prepared the manuscript, and vouch for the completeness and accuracy of the data and analyses. The study was conducted in accordance with the protocol.
Dose-Escalation Phase
PLX4032 was initially in a crystalline formulation. In the dose-escalation phase of the study, which involved several consecutively enrolled groups of three to six patients, the first group received 200 mg of PLX4032 by mouth daily; subsequent groups received the drug at higher doses, according to a dose-escalation scheme. This formulation was found to have poor bioavailability (see the Results section), and enrollment for the dose-escalation phase was halted while the drug was reformulated as a highly bioavailable microprecipitated bulk powder, initially as a 40-mg capsule and subsequently as 80-mg and 120-mg capsules, as well as 240-mg tablets. Enrollment was resumed, with newly enrolled patients receiving the microprecipitated-bulk-powder formulation at a dose of 160 mg (two 80-mg capsules) twice daily, with subsequent escalation.
Patients received continuous therapy with PLX4032 unless unacceptable side effects or disease progression occurred. Doses were not escalated unless the patients receiving the highest current dose had been observed for at least 4 weeks and dose-limiting side effects had been reported in fewer than a third. Dose escalation in a given patient was permitted if the safety and adverse-effect profile had been established for the next highest dose. The recommended phase 2 dose was defined as the highest dose at which no more than one of six patients had dose-limiting side effects.
Extension Phase
Once the recommended phase 2 dose had been identified, an extension cohort was treated at this dose. In this cohort, all patients had melanoma and a prospectively identified V600E BRAF mutation. The primary objective in the extension cohort was to determine the response rate. Secondary objectives were to define the toxicity and pharmacokinetics of PLX4032 more precisely and to obtain data on pharmacodynamic effects.
Patients
Eligibility criteria included the provision of written informed consent, an age of 18 years or older, solid tumors confirmed histologically that were refractory to standard therapy or for which standard or curative therapy did not exist, Eastern Cooperative Oncology Group performance status score of 0 (able to be fully active and carry out all predisease activities without restriction) or 1 (unable to perform physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, such as light housework or office work),19 life expectancy of 3 months or longer, absence of known progressing or unstable brain metastases, and adequate hematologic, hepatic, and renal function.
The dose-escalation phase of the trial was open to patients with any type of tumor, although patients who had melanomas with the V600E mutation in BRAF were overrepresented because of the selective activity of PLX4032 against such tumors in preclinical testing. For the extension cohort, eligibility was restricted to patients with melanomas harboring a V600E BRAF mutation, as ascertained by means of a polymerase-chain-reaction assay (TaqMan, Applied Biosystems). This assay involves hybridizing a probe specific to the 1799T→A substitution that results in the V600E BRAF mutation with DNA isolated from formalin-fixed, paraffin-embedded tumor tissue and determining the presence or absence of amplification after repeated chain-reaction cycles.20
Study Assessments
Safety evaluations were conducted at baseline, day 8, day 15, day 29, and every 4 weeks thereafter. These evaluations included a physical examination, electrocardiography, laboratory studies that included a complete blood count, clinical chemical testing, and urinalysis. Adverse events were graded according to the Common Terminology Criteria for Adverse Events (version 3.0) (http://ctep.info.nih.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf). During the trial, squamous-cell carcinoma, keratoacanthoma type, was observed in several patients (see the Results section). As a result, the protocol was amended to ensure that patients underwent dermatologic evaluations at baseline and every 2 months during the study; computed tomographic (CT) scans of the chest were analyzed for the appearance of new lesions suggestive of a primary cancer.
CT studies were performed at 8-week intervals during therapy in all patients and at the end of the first 4 weeks of therapy in some patients. The findings were judged according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0. A complete response was defined as the disappearance of all target lesions, and a partial response as a decrease by at least 30% in the sum of the largest diameter of each target lesion, relative to the corresponding sum at baseline. Progressive disease was defined as an increase by at least 20% in the sum of the largest diameter of each target lesion, relative to the smallest corresponding diameter recorded since the start of treatment, or the appearance of one or more new lesions. Stable disease was defined as the absence of shrinkage sufficient for a partial response and the absence of enlargement sufficient for progressive disease, relative to the corresponding sum at baseline. Progression-free survival was defined as the time from the first day of treatment to the first documentation of disease progression or death, whichever occurred first.
Pharmacokinetic assessments were made on day 1 and day 15 of the first 4 weeks of therapy, and single plasma samples were obtained every 4 weeks during the study. Plasma samples were analyzed by means of high-performance liquid chromatography, with detection by means of mass spectroscopy.
Patients in the dose-escalation phase who were receiving a dose greater than 160 mg twice daily and patients in the extension cohort underwent 18F-fluorodeoxyglucose–positron-emission tomography (FDG-PET) at baseline and on day 15 of the first 4 weeks of therapy. Selected patients underwent tumor biopsy before the start of therapy as well as on day 15. Biopsy specimens were immediately fixed in formalin for analysis of phosphorylated extracellular signal-regulated kinase (ERK), the protein cyclin D1, and the monoclonal antibody Ki-67 by means of immunohistochemistry. The sampled tumors were cutaneous or superficial lymph-node lesions; except in the case of one patient, sequential biopsy specimens were not taken from the same lesion.
Statistical Analysis
For the primary end point of a partial or complete response in the extension cohort, we calculated that a sample of 32 patients would provide 95% confidence (α=0.05), with 80% power (β=0.20), that an observed response rate of 40% would be consistent with a true response rate of more than 10%, which was considered justification for further study. For this report, January 31, 2010, was the cutoff date for the safety and efficacy follow-up.
Results
Patients
Fifty-five patients were enrolled in the dose-escalation phase of the study (see Fig. 2 in the Supplementary Appendix, available with the full text of this article at NEJM.org); 32 additional patients with metastatic melanoma that carried the V600E BRAF mutation were treated at the recommended phase 2 dose in the extension phase (Table 1Table 1
Baseline Characteristics of the Patients, According to Study Cohort.). The majority of patients (49 of 55 [89%]) in the dose-escalation cohort had metastatic melanoma; 3 of the remaining 6 patients had papillary thyroid cancer that carried the V600E BRAF mutation. Screening for the V600E BRAF mutations was not a requirement for study entry during the dose-escalation phase, but throughout the trial, an increasing number of patients were prospectively identified as having the mutation (for a total of 16 of the 21 patients with melanoma who were enrolled in the groups receiving 240 mg twice daily to 1120 mg twice daily).The initial crystalline formulation of PLX4032 was found to have no dose-limiting side effects or antitumor activity at doses of 200 mg daily to 1600 mg twice daily in consecutively enrolled groups of patients. Since the serum levels detected were lower than the levels predicted in preclinical models to be effective, a microprecipitated-bulk-powder formulation with substantially higher bioavailability was developed and used for the remainder of the study; the lowest dose was 160 mg twice daily, and escalated doses were 240, 320 or 360, 720, and 1120 mg twice daily (Fig. 2 in the Supplementary Appendix). Patients who had been receiving the crystalline formulation were switched to the microprecipitated-bulk-powder formulation. The protocol allowed the dose to be reduced if side effects developed.
Once the recommended phase 2 dose was established for the microprecipitated-bulk-powder formulation in the dose-escalation cohort, the extension cohort was enrolled. All patients in the extension cohort had melanoma carrying the V600E BRAF mutation (Table 1).
Adverse Events
During the latter part of the dose-escalation phase of the trial, when the microprecipitated-bulk-powder formulation of PLX4032 was used, dose-limiting toxic effects were not observed until a dose of 720 mg twice daily was given. At the next-highest dose given to one group of patients, 1120 mg twice daily, four of the six patients had dose-limiting side effects: three patients with grade 3 rash (two of whom also had grade 3 fatigue) and one patient with grade 3 arthralgia (Table 2Table 2
Drug-Related Adverse Events of Grade 2 or Higher Reported in More Than 5% of the 87 Study Patients, According to the Dose of PLX4032 Given Twice Daily.). A dose of 960 mg twice daily was evaluated and determined to be tolerated in the first six patients given the dose, so it was established as the recommended phase 2 dose for the extension cohort. Those six patients were included as the first six patients in the extension cohort. In the extension cohort, 13 patients (41%) required a dose reduction during therapy (to 720 mg twice daily in 10 patients, to 600 mg twice daily in 1 patient, and to 480 mg twice daily in 2 patients). The most common PLX4032-related grade 2 or 3 side effects observed were arthralgia, rash, nausea, photosensitivity, fatigue, cutaneous squamous-cell carcinoma, pruritus, and palmar–plantar dysesthesia (Table 2). In total, 89% of all side effects were grade 1 or 2. Rashes were evenly distributed among the face or neck, trunk, and extremities.Eight patients in the dose-escalation cohort (15%) and 10 patients in the extension cohort (31%) had cutaneous squamous-cell carcinomas, with a total of 35 carcinomas. These were reviewed centrally, and all but one either were keratoacanthoma type or had features of a keratoacanthoma. The median time to the appearance of a cutaneous squamous-cell carcinoma was 8 weeks; the majority of the carcinomas were resected, and in no case did they lead to discontinuation of treatment. No squamous-cell carcinomas at other organ sites were observed during the study.
Pharmacokinetics
Pharmacokinetic analyses revealed that exposure increased with the dose throughout the range of doses of the microprecipitated-bulk-powder formulation that were administered, with exposure being proportional to dose for doses of 240 mg twice daily through 960 mg twice daily. At the recommended phase 2 dose, 960 mg twice daily, the mean (±SD) area under the plasma concentration–time curve over a 24-hour period (AUC0–24) was 1741±639 μM×hour (Figure 1AFigure 1
Mean PLX4032 Concentrations over a 24-Hour Period.), and the mean maximum concentration at steady state was 86±32 μM (Figure 1B). The mean PLX4032 level on day 15, after repeated dosing, was six to nine times the mean level on day 1, and its mean half-life was approximately 50 hours (range, 30 to 80). With the twice-daily dosing regimen, all patients were exposed to relatively constant daily levels of the drug at steady state.Pharmacodynamics
Tumor-biopsy specimens that had been obtained at baseline and at day 15 were available for seven of the patients in the extension cohort who were receiving PLX4032 at the recommended phase 2 dose. Tumor levels of phosphorylated ERK, cyclin D1, and Ki-67 were markedly reduced at day 15 as compared with baseline in all specimens tested (Figure 2AFigure 2
Representative Findings of the Effect of PLX4032 at the Recommended Phase 2 Dose in Study Patients with Melanoma That Carried the V600E Mutation.). This finding suggests that PLX4032 inhibited the MAP kinase pathway, resulting in decreased cyclin D1 levels and decreased proliferation. In virtually all patients, a marked decrease in tumor uptake of FDG was noted at day 15 (Figure 2B).Tumor Response
Dose-Escalation Phase
No responses were observed at doses of 160 mg twice daily of the microprecipitated-bulk-powder formulation or at any dose of the crystalline formulation. Of the patients receiving doses of 240 mg or more twice daily, 16 had melanoma with tumors that harbored the V600E BRAF mutation. Among these 16 patients, a partial or complete response was seen in the 1 patient receiving 240 mg twice daily, 2 of the 4 patients receiving 320 or 360 mg twice daily, 4 of the 6 patients receiving 720 mg twice daily, and 4 of the 5 patients receiving 1120 mg twice daily. The overall response rate was 69% (11 of 16 patients), with 10 partial responses and 1 complete response (Fig. 1A in the Supplementary Appendix). Responses were seen at all sites of metastatic disease, including the liver, small bowel, and bone (Figure 2C). The duration of the response ranged from 2 to more than 18 months, with 4 patients still having a partial or complete response at the data cut-off date (Fig. 1B in the Supplementary Appendix). In addition to the patients with melanoma, the 3 patients with papillary thyroid cancer had a partial or complete response, with the response lasting 8 months in 1 patient (who was progression-free for 12 months) and stable disease lasting 11 and 13 months in each of the other 2 patients.
A total of 5 patients with metastatic melanoma whose tumors did not have a BRAF mutation received doses of 240 mg or more twice daily. None had evidence of tumor regression during the study; 4 had progressive disease within the first 2 months of treatment.
Extension Phase
The extension cohort consisted solely of patients who had melanoma with the V600E BRAF mutation. All were treated at the recommended phase 2 dose of 960 mg twice daily. A total of 26 of the 32 patients had a response (81%), with a complete response in 2 patients and a partial response in 24 patients (Figure 3AFigure 3
Antitumor Response in Each of the 32 Patients in the Extension Cohort.). Among patients with symptomatic metastatic disease, improvement of symptoms, such as a reduced need for narcotics for pain in 3 patients, was reported within 1 to 2 weeks. As in the dose-escalation cohort, we observed tumor responses in visceral organs and bone metastases as well as more typically responsive sites such as the lungs and lymph nodes. Responses were also routinely observed in patients with elevated lactate dehydrogenase levels (10 partial responses among the 13 patients) and in patients who had received more than one previous type of therapy (11 partial responses among the 16 patients). To date, 16 of the 32 patients are still in the study; the estimated median progression-free survival among these patients is more than 7 months, on the basis of a Kaplan–Meier analysis. The estimated median overall survival has not been reached.Discussion
Our trial shows that therapy targeting tumors containing activating V600E BRAF mutations can induce complete or partial tumor regression in patients. PLX4032 induced complete or partial tumor regression in 81% of patients who had melanoma with the V600E BRAF mutation. Responses were observed at all sites of disease, including the bone, liver, and small bowel. During the dose-escalation phase of the trial, we also saw responses in patients who were receiving doses below the recommended phase 2 dose. These efficacy data are particularly encouraging in light of the high disease burden in most of our patients and the presence of symptomatic disease in many of them.
Most side effects related to PLX4032 appeared to be proportional to the dose and exposure to the drug. Cutaneous side effects, fatigue, and arthralgia predominated. In the extension cohort, at the dose of 960 mg twice daily, approximately 40% of patients required a short- or long-term reduction in dose to 720 mg, 600 mg, or 480 mg twice daily, many for grade 2 side effects. Squamous-cell carcinoma, keratoacanthoma type, developed in a total of 10 of 32 patients (31%); we also observed squamous-cell carcinoma, keratoacanthoma type, in patients in the dose-escalation cohort. The characteristic rapid eruption of individual, dome-shaped, nonpigmented lesions and histologic findings were present in each case. Usually, squamous-cell carcinoma, keratoacanthoma type, are well-differentiated tumors with very low invasive potential and no metastatic potential; our data do not allow us to determine their behavior in patients receiving PLX4032. Recent data show that BRAF inhibitors can activate the MAP kinase pathway in cells that lack a BRAF mutation.21-23 This activation may pertain to some of the side effects seen with PLX4032.
Though the early response to PLX4032 seems to occur reliably, responsive tumors can develop resistance to treatment. Among the patients in the dose-escalation cohort who had a response to treatment, the duration of the response ranged from 2 to more than 18 months. The mechanism of secondary tumor resistance is not yet known. We also observed that in some patients with V600E BRAF mutations, the tumors showed resistance without evidence of an early response. The mechanism of this primary refractory state is currently under investigation. To date, we have not seen “gatekeeper” BRAF mutations in resistant tumors, although this issue requires more investigation.
Sorafenib, which inhibits BRAF (both the wild type and the V600E mutant) and v-raf-1 murine leukemia viral oncogene homologue 1 (RAF1), has been studied in melanoma. In animal models of melanoma, sorafenib has not shown selective activity against tumors carrying BRAF mutations, and in clinical trials, sorafenib used either alone or in combination with chemotherapy has not had significant antimelanoma effects.24-27 It is possible that the non-BRAF effects of sorafenib mediate side effects that limit the likelihood of achieving a drug concentration that is high enough to inhibit the V600E BRAF mutation.
It is now clear that melanomas can be categorized by specific molecular changes that drive their proliferation.28 The overriding hypothesis is that inhibition of the activated pathway in the individual tumor will lead to tumor regression. There is recent preliminary evidence that imatinib can induce regression in 33% of the small proportion of melanomas driven by mutations in KIT (the v-kit Hardy–Zuckerman 4 feline sarcoma viral oncogene homologue).29 In our study, PLX4032 induced responses in the vast majority of melanomas caused by BRAF mutations, which constitute 40 to 60% of all melanomas. We do not yet know whether treatment with PLX4032 will improve overall survival; an ongoing phase 3 trial (ClinicalTrials.gov number, NCT01006980) is addressing that question.
Supported by Plexxikon and Roche Pharmaceuticals.
Drs. Flaherty, Puzanov, Kim, Ribas, McArthur, Sosman, O'Dwyer, and Chapman report the receipt by their institutions of grant support from Plexxikon to conduct this clinical trial; Drs. Flaherty, Puzanov, Kim, Ribas, Sosman, and Chapman report receiving consulting fees or reimbursement for travel expenses from Roche Pharmaceuticals; Dr. Sosman reports pending receipt of grant support from Roche Pharmaceuticals; Dr. O'Dwyer reports receiving grant support from Plexxikon; Drs. Lee and Grippo report being employees of Roche Pharmaceuticals; and Dr. Nolop reports being an employee of Plexxikon, holding equity in the company, and receiving reimbursement for travel expenses from the company. No other potential conflict of interest relevant to this article was reported.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
We thank Drs. Katherine Nathanson and Xiaowei Xu (of the University of Pennsylvania) for leading the analysis of tumors for BRAF mutations and the immunohistochemical analysis of phosphorylated ERK and Ki-67 during the dose-escalation part of the study, Drs. Astrid Koehler and Michael Stumm (of Roche Pharmaceuticals) for leading these analyses during the extension part of the study, and Dr. Ruben Ayala (of Roche Pharmaceuticals) for the pharmacokinetic analysis.
Source Information
From the Abramson Cancer Center of the University of Pennsylvania, Philadelphia (K.T.F., P.J.O.); Massachusetts General Hospital Cancer Center, Boston (K.T.F.); Vanderbilt University, Nashville (I.P., J.A.S.); the University of Texas M.D. Anderson Cancer Center, Houston (K.B.K.); UCLA, Los Angeles (A.R.); Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia (G.A.M.); Roche Pharmaceuticals, Nutley, NJ (R.J.L., J.F.G.); Plexxikon, Berkeley, CA (K.N.); and Memorial Sloan-Kettering Cancer Center, New York (P.B.C.).
Address reprint requests to Dr. Flaherty at Massachusetts General Hospital Cancer Center, 55 Fruit St., Yawkey 9E, Boston, MA 02114, or at kflaherty@partners.org.
- References
References
1
Comis RL . DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Rep 1976;60:165-176
Medline2
Atkins MB ,Lotze MT ,Dutcher JP , et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-2116
Web of Science | Medline3
Middleton MR ,Grob JJ ,Aaronson N , et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-166[Erratum, J Clin Oncol 2000;18:2351.]
Web of Science | Medline4
Bedikian AY ,Millward M ,Pehamberger H , et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738-4745
CrossRef | Web of Science | Medline5
Davies H ,Bignell GR ,Cox C , et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954
CrossRef | Web of Science | Medline6
Nikiforova MN ,Kimura ET ,Gandhi M , et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-5404
CrossRef | Web of Science | Medline7
Fukushima T ,Suzuki S ,Mashiko M , et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003;22:6455-6457
CrossRef | Web of Science | Medline8
Cohen Y ,Xing M ,Mambo E , et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003;95:625-627
CrossRef | Web of Science | Medline9
Yuen ST ,Davies H ,Chan TL , et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002;62:6451-6455
Web of Science | Medline10
Oliveira C ,Pinto M ,Duval A , et al. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 2003;22:9192-9196
CrossRef | Web of Science | Medline11
Wang L ,Cunningham JM ,Winters JL , et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003;63:5209-5212
Web of Science | Medline12
Tannapfel A ,Sommerer F ,Benicke M , et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003;52:706-712
CrossRef | Web of Science | Medline13
Cho NY ,Choi M ,Kim BH ,Cho YM ,Moon KC ,Kang GH . BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer 2006;119:1858-1862
CrossRef | Web of Science | Medline14
Singer G ,Oldt R III ,Cohen Y , et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95:484-486
CrossRef | Web of Science | Medline15
Honecker F ,Wermann H ,Mayer F , et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol 2009;27:2129-2136
CrossRef | Web of Science | Medline16
Kimura ET ,Nikiforova MN ,Zhu Z ,Knauf JA ,Nikiforov YE ,Fagin JA . High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-1457
Web of Science | Medline17
Tsai J ,Lee JT ,Wang W , et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008;105:3041-3046
CrossRef | Web of Science | Medline18
Sondergaard JN ,Nazarian R ,Wang Q , et al. Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 2010;8:39-39
CrossRef | Web of Science | Medline19
Oken MM ,Creech RH ,Tormey DC , et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655
CrossRef | Web of Science | Medline20
Koch WH . Technology platforms for pharmacogenomic diagnostic assays. Nat Rev Drug Discov 2004;3:749-761
CrossRef | Web of Science | Medline21
Heidorn SJ ,Milagre C ,Whittaker S , et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140:209-221
CrossRef | Web of Science | Medline22
Poulikakos PI ,Zhang C ,Bollag G ,Shokat KM ,Rosen N . RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427-430
CrossRef | Web of Science | Medline23
Hatzivassiliou G ,Song K ,Yen I , et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431-435
CrossRef | Web of Science | Medline24
Wilhelm SM ,Carter C ,Tang L , et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109
CrossRef | Web of Science | Medline25
Eisen T ,Ahmad T ,Flaherty KT , et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006;95:581-586
CrossRef | Web of Science | Medline26
McDermott DF ,Sosman JA ,Gonzalez R , et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 2008;26:2178-2185
CrossRef | Web of Science | Medline27
Hauschild A ,Agarwala SS ,Trefzer U , et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823-2830
CrossRef | Web of Science | Medline28
Curtin JA ,Fridlyand J ,Kageshita T , et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-2147
Full Text | Web of Science | Medline29
Carvajal RD ,Chapman PB ,Wolchok JD , et al. A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. J Clin Oncol 2009;27:Suppl:15S-15S
CrossRef | Web of Science
- Citing Articles (321)
Citing Articles
1
Harkanwal Halait, Kelli DeMartin, Sweta Shah, Stephen Soviero, Rachel Langland, Suzanne Cheng, Grantland Hillman, Lin Wu, H. Jeffrey Lawrence. (2012) Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma. Diagnostic Molecular Pathology 21:1, 1-8
CrossRef2
Keith T. Flaherty. (2012) Targeting Metastatic Melanoma. Annual Review of Medicine 63:1, 171-183
CrossRef3
Andree Yeramian, Anabel Sorolla, Ana Velasco, Maria Santacana, Xavier Dolcet, Joan Valls, Leandre Abal, Sara Moreno, Ramón Egido, Josep M. Casanova, Susana Puig, Ramón Vilella, Antonio Llombart-Cussac, Xavier Matias-Guiu, Rosa M. Martí. (2012) Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway. International Journal of Cancer 130:4, 967-978
CrossRef4
Timothy A. Yap, Paul Workman. (2012) Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics. Annual Review of Pharmacology and Toxicology 52:1, 549-573
CrossRef5
Dummer, Reinhard, Rinderknecht, Jeannine, Goldinger, Simone M., . (2012) Ultraviolet A and Photosensitivity during Vemurafenib Therapy. New England Journal of Medicine 366:5, 480-481
Full Text6
Rolando Pérez
Lorenzo, Bin Zheng. (2012) Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma. Bioscience Reports 32:1, 25-33
CrossRef7
Sojun Hoshimoto, Mark B. Faries, Donald L. Morton, Tatsushi Shingai, Christine Kuo, He-jing Wang, Robert Elashoff, Nicola Mozzillo, Mark C. Kelley, John F. Thompson, Jeffrey E. Lee, Dave S. B. Hoon. (2012) Assessment of Prognostic Circulating Tumor Cells in a Phase III Trial of Adjuvant Immunotherapy After Complete Resection of Stage IV Melanoma. Annals of Surgery 255:2, 357-362
CrossRef8
John T. Lee, Meenhard Herlyn. (2012) MEK'ing the Most of p53 Reactivation Therapy in Melanoma. Journal of Investigative Dermatology 132:2, 263-265
CrossRef9
Q. Tian, N. D. Price, L. Hood. (2012) Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. Journal of Internal Medicine 271:2, 111-121
CrossRef10
David Capper, Anna Sophie Berghoff, Manuel Magerle, Aysegül Ilhan, Adelheid Wöhrer, Monika Hackl, Josef Pichler, Stefan Pusch, Jochen Meyer, Antje Habel, Peter Petzelbauer, Peter Birner, Andreas Deimling, Matthias Preusser. (2012) Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathologica 123:2, 223-233
CrossRef11
Sarah-Jane Schramm, Anna E Campain, Richard A Scolyer, Yee Hwa Yang, Graham J Mann. (2012) Review and Cross-Validation of Gene Expression Signatures and Melanoma Prognosis. Journal of Investigative Dermatology 132:2, 274-283
CrossRef12
Tiziana Negri, Silvia Brich, Elena Conca, Fabio Bozzi, Marta Orsenigo, Silvia Stacchiotti, Marco Alberghini, Valentina Mauro, Alessandro Gronchi, Giuseppina F. Dusio, Giuseppe Pelosi, Piero Picci, Paolo G. Casali, Marco A. Pierotti, Silvana Pilotti. (2012) Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma. Genes, Chromosomes and Cancer 51:2, 111-126
CrossRef13
Mythili Koneru, Richard D Carvajal. (2012) A new era for the management of metastatic melanoma. Expert Review of Dermatology 7:1, 27-35
CrossRef14
M. Falk, C. Hallas, M. Tiemann. (2012) Molekularpathologische Grundlagen für die Therapie des NSCLC. best practice onkologie 7:1, 4-11
CrossRef15
K Sakaizawa, Y Goto, Y Kiniwa, A Uchiyama, K Harada, S Shimada, T Saida, S Ferrone, M Takata, H Uhara, R Okuyama. (2012) Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. British Journal of Cancer
CrossRef16
O. Weigert, A. A. Lane, L. Bird, N. Kopp, B. Chapuy, D. van Bodegom, A. V. Toms, S. Marubayashi, A. L. Christie, M. McKeown, R. M. Paranal, J. E. Bradner, A. Yoda, C. Gaul, E. Vangrevelinghe, V. Romanet, M. Murakami, R. Tiedt, N. Ebel, E. Evrot, A. De Pover, C. H. Regnier, D. Erdmann, F. Hofmann, M. J. Eck, S. E. Sallan, R. L. Levine, A. L. Kung, F. Baffert, T. Radimerski, D. M. Weinstock. (2012) Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. Journal of Experimental Medicine
CrossRef17
Martin W. Rowbottom, Raffaella Faraoni, Qi Chao, Brian T. Campbell, Andiliy G. Lai, Eduardo Setti, Maiko Ezawa, Kelly G. Sprankle, Sunny Abraham, Lan Tran, Brian Struss, Michael Gibney, Robert C. Armstrong, Ruwanthi N. Gunawardane, Ronald R. Nepomuceno, Ianina Valenta, Helen Hua, Michael F. Gardner, Merryl D. Cramer, Dana Gitnick, Darren E. Insko, Julius L. Apuy, Susan Jones-Bolin, Arup K. Ghose, Torsten Herbertz, Mark A. Ator, Bruce D. Dorsey, Bruce Ruggeri, Michael Williams, Shripad Bhagwat, Joyce James, Mark W. Holladay. (2012) Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E. Journal of Medicinal Chemistry120123085222000
CrossRef18
Elchin S. Julfayev, Ryan J. McLaughlin, Yi-Ping Tao, William A. McLaughlin. (2012) KB-Rank: efficient protein structure and functional annotation identification via text query. Journal of Structural and Functional Genomics
CrossRef19
Su, Fei, Viros, Amaya, Milagre, Carla, Trunzer, Kerstin, Bollag, Gideon, Spleiss, Olivia, Reis-Filho, Jorge S., Kong, Xiangju, Koya, Richard C., Flaherty, Keith T., Chapman, Paul B., Kim, Min Jung, Hayward, Robert, Martin, Matthew, Yang, Hong, Wang, Qiongqing, Hilton, Holly, Hang, Julie S., Noe, Johannes, Lambros, Maryou, Geyer, Felipe, Dhomen, Nathalie, Niculescu-Duvaz, Ion, Zambon, Alfonso, Niculescu-Duvaz, Dan, Preece, Natasha, Robert, Lídia, Otte, Nicholas J., Mok, Stephen, Kee, Damien, Ma, Yan, Zhang, Chao, Habets, Gaston, Burton, Elizabeth A., Wong, Bernice, Nguyen, Hoa, Kockx, Mark, Andries, Luc, Lestini, Brian, Nolop, Keith B., Lee, Richard J., Joe, Andrew K., Troy, James L., Gonzalez, Rene, Hutson, Thomas E., Puzanov, Igor, Chmielowski, Bartosz, Springer, Caroline J., McArthur, Grant A., Sosman, Jeffrey A., Lo, Roger S., Ribas, Antoni, Marais, Richard, . (2012) RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors. New England Journal of Medicine 366:3, 207-215
Full Text20
T. L. Biechele, R. M. Kulikauskas, R. A. Toroni, O. M. Lucero, R. D. Swift, R. G. James, N. C. Robin, D. W. Dawson, R. T. Moon, A. J. Chien. (2012) Wnt/ -Catenin Signaling and AXIN1 Regulate Apoptosis Triggered by Inhibition of the Mutant Kinase BRAFV600E in Human Melanoma. Science Signaling 5:206, ra3-ra3
CrossRef21
Alexander M. M. Eggermont, Caroline Robert. (2012) Melanoma in 2011: A new paradigm tumor for drug development. Nature Reviews Clinical Oncology
CrossRef22
Vasiliki A Nikolaou, Alexander J Stratigos, Keith T Flaherty, Hensin Tsao. (2012) Melanoma: New Insights and New Therapies. Journal of Investigative Dermatology
CrossRef23
E. Tiacci, G. Schiavoni, F. Forconi, A. Santi, L. Trentin, A. Ambrosetti, D. Cecchini, E. Sozzi, P. Francia di Celle, C. Di Bello, A. Pulsoni, R. Foa, G. Inghirami, B. Falini. (2012) Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood 119:1, 192-195
CrossRef24
A P Algazi, J S Weber, S C Andrews, P Urbas, P N Munster, R C DeConti, J Hwang, V K Sondak, J L Messina, T McCalmont, A I Daud. (2012) Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. British Journal of Cancer 106:1, 85-91
CrossRef25
Hwangseo Park, Seunghee Hong, Sungwoo Hong. (2012) Nocodazole is a High-Affinity Ligand for the Cancer-Related Kinases ABL, c-KIT, BRAF, and MEK. ChemMedChem 7:1, 53-56
CrossRef26
Camila Ferreira de Souza, Alice Santana Morais, Miriam Galvonas Jasiulionis. (2012) Biomarkers as Key Contributors in Treating Malignant Melanoma Metastases. Dermatology Research and Practice 2012, 1-14
CrossRef27
Shunsuke Ozaki, Takuma Minamisono, Taro Yamashita, Takashi Kato, Ikuo Kushida. (2012) Supersaturation-nucleation behavior of poorly soluble drugs and its impact on the oral absorption of drugs in thermodynamically high-energy forms. Journal of Pharmaceutical Sciences 101:1, 214-222
CrossRef28
W. Deng, Y. N. Vashisht Gopal, A. Scott, G. Chen, S. E. Woodman, M. A. Davies. (2012) Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell & Melanoma Researchno-no
CrossRef29
Libero Santarpia, Scott M Lippman, Adel K El-Naggar. (2012) Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets 16:1, 103-119
CrossRef30
Ichiro Yajima, Mayuko Y. Kumasaka, Nguyen Dinh Thang, Yuji Goto, Kozue Takeda, Osamu Yamanoshita, Machiko Iida, Nobutaka Ohgami, Haruka Tamura, Yoshiyuki Kawamoto, Masashi Kato. (2012) RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy. Dermatology Research and Practice 2012, 1-5
CrossRef31
Marie-Annick Reginster, Claudine Pierard-Franchimont, Gérald E. Piérard, Pascale Quatresooz. (2012) Molecular Dermatopathology in Malignant Melanoma. Dermatology Research and Practice 2012, 1-6
CrossRef32
Irene Sánchez-Hernández, Pablo Baquero, Laura Calleros, Antonio Chiloeches. (2012) Dual inhibition of V600EBRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism. Cancer Letters 314:2, 244-255
CrossRef33
Felipe Ades, Otto Metzger-Filho. (2012) Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma. Dermatology Research and Practice 2012, 1-9
CrossRef34
Y Shao, A E Aplin. (2012) ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity. Cell Death and Disease 3:1, e253
CrossRef35
M Colombino, P Sperlongano, F Izzo, F Tatangelo, G Botti, A Lombardi, M Accardo, L Tarantino, I Sordelli, M Agresti, A Abbruzzese, M Caraglia, G Palmieri. (2012) BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death and Disease 3:1, e259
CrossRef36
Amber L. Shada, Dustin M. Walters, Shannon N. Tierney, Craig L. Slingluff. (2012) Surgical resection for bulky or recurrent axillary metastatic melanoma. Journal of Surgical Oncology 105:1, 21-25
CrossRef37
Arman Jahangiri, Manish K. Aghi. (2012) Biomarkers predicting tumor response and evasion to anti-angiogenic therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1825:1, 86-100
CrossRef38
M. Schlumberger, S. I. Sherman. (2012) ENDOCRINE TUMOURS: Approach to the patient with advanced differentiated thyroid cancer. European Journal of Endocrinology 166:1, 5-11
CrossRef39
Ken Dutton-Regester, Lauren G. Aoude, Derek J. Nancarrow, Mitchell S. Stark, Linda O'Connor, Cathy Lanagan, Gulietta M. Pupo, Varsha Tembe, Candace D. Carter, Michael O'Rourke, Richard A. Scolyer, Graham J. Mann, Christopher W. Schmidt, Adrian Herington, Nicholas K. Hayward. (2012) Identification of TFG (TRK-fused gene) as a putative metastatic melanoma tumor suppressor gene. Genes, Chromosomes and Cancern/a-n/a
CrossRef40
Gayane Badalian-Very, Jo-Anne Vergilio, Barbara A. Degar, Carlos Rodriguez-Galindo, Barrett J. Rollins. (2012) Recent advances in the understanding of Langerhans cell histiocytosis. British Journal of Haematology 156:2, 163-172
CrossRef41
Lu Si, Yan Kong, Xiaowei Xu, Keith T. Flaherty, Xinan Sheng, Chuanliang Cui, Zhihong Chi, Siming Li, Lili Mao, Jun Guo. (2012) Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort. European Journal of Cancer 48:1, 94-100
CrossRef42
Roger S Lo. (2012) Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas. Pharmacogenomics 13:2, 125-128
CrossRef43
Miriam Molina-Arcas, Julian Downward. (2012) How to Fool a Wonder Drug: Truncate and Dimerize. Cancer Cell 21:1, 7-9
CrossRef44
Ha Linh Vu, Andrew E. Aplin. (2012) The Yin-Yang of RAF inhibitors. Pigment Cell & Melanoma Researchno-no
CrossRef45
Zhenyu Ji, Keith T. Flaherty, Hensin Tsao. (2012) Targeting the RAS pathway in melanoma. Trends in Molecular Medicine 18:1, 27-35
CrossRef46
S. Kruijff, H.J. Hoekstra. (2012) The current status of S-100B as a biomarker in melanoma. European Journal of Surgical Oncology (EJSO)
CrossRef47
Joannes FM Jacobs, Stefan Nierkens, Carl G Figdor, I Jolanda M de Vries, Gosse J Adema. (2012) Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?. The Lancet Oncology 13:1, e32-e42
CrossRef48
R.M. Martí, A. Sorolla, A. Yeramian. (2012) Nuevas dianas terapéuticas en el melanoma. Actas Dermo-Sifiliográficas
CrossRef49
Nicolas Ortonne. (2012) Actualité en pathologie dermatologique pratique. Revue Francophone des Laboratoires 2012:438, 35-46
CrossRef50
Carsten Grüllich, Christof von Kalle. (2012) Recent Developments and Future Perspectives of Personalized Oncology. Onkologie 35:s1, 4-7
CrossRef51
Reinhard Dummer, Keith T. Flaherty. (2012) Resistance patterns with tyrosine kinase inhibitors in melanoma. Current Opinion in Oncology1
CrossRef52
Chia-Chun Hsu, Yang-Chang Wu, Lynn Farh, Ying-Chi Du, Wei-Kung Tseng, Chau-Chung Wu, Fang-Rong Chang. (2012) Physalin B from Physalis angulata triggers the NOXA-related apoptosis pathway of human melanoma A375 cells. Food and Chemical Toxicology
CrossRef53
Hwangseo Park, Yujeong Jeong, Sungwoo Hong. (2012) Structure-based de novo design and biochemical evaluation of novel BRAF kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 22:2, 1027-1030
CrossRef54
A. Bottos, M. Martini, F. Di Nicolantonio, V. Comunanza, F. Maione, A. Minassi, G. Appendino, F. Bussolino, A. Bardelli. (2011) PNAS Plus: Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proceedings of the National Academy of Sciences
CrossRef55
Mitchell S Stark, Susan L Woods, Michael G Gartside, Vanessa F Bonazzi, Ken Dutton-Regester, Lauren G Aoude, Donald Chow, Chris Sereduk, Natalie M Niemi, Nanyun Tang, Jonathan J Ellis, Jeffrey Reid, Victoria Zismann, Sonika Tyagi, Donna Muzny, Irene Newsham, YuanQing Wu, Jane M Palmer, Thomas Pollak, David Youngkin, Bradford R Brooks, Catherine Lanagan, Christopher W Schmidt, Bostjan Kobe, Jeffrey P MacKeigan, Hongwei Yin, Kevin M Brown, Richard Gibbs, Jeffrey Trent, Nicholas K Hayward. (2011) Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nature Genetics
CrossRef56
Dorothy M. K. Keefe, Emma H. Bateman. (2011) Tumor control versus adverse events with targeted anticancer therapies. Nature Reviews Clinical Oncology
CrossRef57
Kai-Jye Lou. (2011) Splicing out BRAF's resistance. Science-Business eXchange 4:48,
CrossRef58
Hugo Lavoie, Marc Therrien. (2011) Cancer: A drug-resistant duo. Nature 480:7377, 329-330
CrossRef59
H. Moch, P. R. Blank, M. Dietel, G. Elmberger, K. M. Kerr, J. Palacios, F. Penault-Llorca, G. Rossi, T. D. Szucs. (2011) Personalized cancer medicine and the future of pathology. Virchows Archiv
CrossRef60
Manish R. Sharma, Richard L. Schilsky. (2011) Role of randomized phase III trials in an era of effective targeted therapies. Nature Reviews Clinical Oncology
CrossRef61
Edward H. Flach, Vito W. Rebecca, Meenhard Herlyn, Keiran S. M. Smalley, Alexander R. A. Anderson. (2011) Fibroblasts Contribute to Melanoma Tumor Growth and Drug Resistance. Molecular Pharmaceutics 8:6, 2039-2049
CrossRef62
Leisl M. Packer, Sareena Rana, Robert Hayward, Thomas O'Hare, Christopher A. Eide, Ana Rebocho, Sonja Heidorn, Matthew S. Zabriskie, Ion Niculescu-Duvaz, Brian J. Druker, Caroline Springer, Richard Marais. (2011) Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Cancer Cell 20:6, 715-727
CrossRef63
Benjamin Scheier, Rodabe Amaria, Karl Lewis, Rene Gonzalez. (2011) Novel therapies in melanoma. Immunotherapy 3:12, 1461-1469
CrossRef64
Thierry Passeron, Jean-Philippe Lacour, Maryline Allegra, Coralie Ségalen, Anne Deville, Antoine Thyss, Damien Giacchero, Jean-Paul Ortonne, Corine Bertolotto, Robert Ballotti, Philippe Bahadoran. (2011) Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?. Experimental Dermatology 20:12, 1030-1032
CrossRef65
Gaëlle Quéreux, Brigitte Dréno. (2011) Fotemustine for the treatment of melanoma. Expert Opinion on Pharmacotherapy 12:18, 2891-2904
CrossRef66
Tamar Nijsten, Robert S Stern. (2011) How Epidemiology Has Contributed to a Better Understanding of Skin Disease. Journal of Investigative Dermatology
CrossRef67
L. V. Sequist, R. S. Heist, A. T. Shaw, P. Fidias, R. Rosovsky, J. S. Temel, I. T. Lennes, S. Digumarthy, B. A. Waltman, E. Bast, S. Tammireddy, L. Morrissey, A. Muzikansky, S. B. Goldberg, J. Gainor, C. L. Channick, J. C. Wain, H. Gaissert, D. M. Donahue, A. Muniappan, C. Wright, H. Willers, D. J. Mathisen, N. C. Choi, J. Baselga, T. J. Lynch, L. W. Ellisen, M. Mino-Kenudson, M. Lanuti, D. R. Borger, A. J. Iafrate, J. A. Engelman, D. Dias-Santagata. (2011) Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Annals of Oncology 22:12, 2616-2624
CrossRef68
Moriah H. Nissan, David B. Solit. (2011) The “SWOT” of BRAF Inhibition in Melanoma: RAF Inhibitors, MEK Inhibitors or Both?. Current Oncology Reports 13:6, 479-487
CrossRef69
Timothy J. Yeatman. (2011) A public/private partnership in personalized cancer care. Journal of Medicine and the Person 9:3, 112-115
CrossRef70
Debyani Chakravarty, Elmer Santos, Mabel Ryder, Jeffrey A. Knauf, Xiao-Hui Liao, Brian L. West, Gideon Bollag, Richard Kolesnick, Tin Htwe Thin, Neal Rosen, Pat Zanzonico, Steven M. Larson, Samuel Refetoff, Ronald Ghossein, James A. Fagin. (2011) Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. Journal of Clinical Investigation 121:12, 4700-4711
CrossRef71
Savithri Ramurthy, Abran Costales, Johanna M. Jansen, Barry Levine, Paul A. Renhowe, Cynthia M. Shafer, Sharadha Subramanian. (2011) Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors. Bioorganic & Medicinal Chemistry Letters
CrossRef72
S. Roychowdhury, M. K. Iyer, D. R. Robinson, R. J. Lonigro, Y.-M. Wu, X. Cao, S. Kalyana-Sundaram, L. Sam, O. A. Balbin, M. J. Quist, T. Barrette, J. Everett, J. Siddiqui, L. P. Kunju, N. Navone, J. C. Araujo, P. Troncoso, C. J. Logothetis, J. W. Innis, D. C. Smith, C. D. Lao, S. Y. Kim, J. S. Roberts, S. B. Gruber, K. J. Pienta, M. Talpaz, A. M. Chinnaiyan. (2011) Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study. Science Translational Medicine 3:111, 111ra121-111ra121
CrossRef73
Poulikos I. Poulikakos, Yogindra Persaud, Manickam Janakiraman, Xiangju Kong, Charles Ng, Gatien Moriceau, Hubing Shi, Mohammad Atefi, Bjoern Titz, May Tal Gabay, Maayan Salton, Kimberly B. Dahlman, Madhavi Tadi, Jennifer A. Wargo, Keith T. Flaherty, Mark C. Kelley, Tom Misteli, Paul B. Chapman, Jeffrey A. Sosman, Thomas G. Graeber, Antoni Ribas, Roger S. Lo, Neal Rosen, David B. Solit. (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480:7377, 387-390
CrossRef74
Miriam Martini, Loredana Vecchione, Salvatore Siena, Sabine Tejpar, Alberto Bardelli. (2011) Targeted therapies: how personal should we go?. Nature Reviews Clinical Oncology
CrossRef75
Ainhoa Mielgo, Laetitia Seguin, Miller Huang, Maria Fernanda Camargo, Sudarshan Anand, Aleksandra Franovic, Sara M Weis, Sunil J Advani, Eric A Murphy, David A Cheresh. (2011) A MEK-independent role for CRAF in mitosis and tumor progression. Nature Medicine 17:12, 1641-1645
CrossRef76
Almass-Houd Aguissa-Touré, Gang Li. (2011) Genetic alterations of PTEN in human melanoma. Cellular and Molecular Life Sciences
CrossRef77
AGNESSA GADELIYA GOODSON, SCOTT R. FLORELL, KENNETH M. BOUCHER, DOUGLAS GROSSMAN. (2011) A Decade of Melanomas: Identification of Factors Associated with Delayed Detection in an Academic Group Practice. Dermatologic Surgery 37:11, 1620-1630
CrossRef78
Ewan R. Brown, Tamasin Doig, Niall Anderson, Thomas Brenn, Val Doherty, Yan Xu, John M.S. Bartlett, John F. Smyth, David W. Melton. (2011) Association of galectin-3 expression with melanoma progression and prognosis. European Journal of Cancer
CrossRef79
Anna Minchom, Kate Young, James Larkin. (2011) Ipilimumab: showing survival benefit in metastatic melanoma. Future Oncology 7:11, 1255-1264
CrossRef80
J. P. Deroose, D. J. Grünhagen, A. N. van Geel, J. H. W. de Wilt, A. M. M. Eggermont, C. Verhoef. (2011) Long-term outcome of isolated limb perfusion with tumour necrosis factor-α for patients with melanoma in-transit metastases. British Journal of Surgery 98:11, 1573-1580
CrossRef81
Jennifer Nam Choi. (2011) Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts. Clinics in Dermatology 29:6, 587-601
CrossRef82
Iván Márquez-Rodas, Salvador Martín Algarra, José Antonio Avilés Izquierdo, Sara Custodio Cabello, Miguel Martín. (2011) A new era in the treatment of melanoma: from biology to clinical practice. Clinical and Translational Oncology 13:11, 787-792
CrossRef83
Jung-min Lee, Jasmine J. Han, Gary Altwerger, Elise C. Kohn. (2011) Proteomics and biomarkers in clinical trials for drug development. Journal of Proteomics 74:12, 2632-2641
CrossRef84
Davide Torti, Livio Trusolino. (2011) Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Molecular Medicine 3:11, 623-636
CrossRef85
Janakiraman Subramanian, Saiama N. Waqar, Ramaswamy Govindan. (2011) Targeted Therapy in Lung Cancer. Journal of Thoracic Oncology 6, S1786-S1788
CrossRef86
Richard L Schilsky. (2011) Drug approval challenges in the age of personalized cancer treatment. Personalized Medicine 8:6, 633-640
CrossRef87
Csaba Gajdos, Martin D McCarter. (2011) Debulking surgery in advanced melanoma. Expert Review of Anticancer Therapy 11:11, 1703-1712
CrossRef88
Ivan Pacheco, Cristina Buzea, Victor Tron. (2011) Towards new therapeutic approaches for malignant melanoma. Expert Reviews in Molecular Medicine 13,
CrossRef89
Keith. T Flaherty, Uma Yasothan, Peter Kirkpatrick. (2011) Vemurafenib. Nature Reviews Drug Discovery 10:11, 811-812
CrossRef90
(2011) Vemurafenib in Melanoma with BRAF V600E Mutation. New England Journal of Medicine 365:15, 1448-1450
Full Text91
Michaela J. Higgins, José Baselga. (2011) Targeted therapies for breast cancer. Journal of Clinical Investigation 121:10, 3797-3803
CrossRef92
Josep M. Llovet, Valerie Paradis, Masatoshi Kudo, Jessica Zucman-Rossi. (2011) Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. Liver Transplantation 17:S2, S67-S71
CrossRef93
Chiara Lucchetti, Flavio Rizzolio, Matteo Castronovo, Giuseppe Toffoli. (2011) Research Highlights. Pharmacogenomics 12:10, 1379-1382
CrossRef94
Bohuslav Melichar, Mario Plebani. (2011) Laboratory medicine: an essential partner in the care of cancer patients. Clinical Chemistry and Laboratory Medicine 49:10, 1575-1578
CrossRef95
Allie H Grossmann, Wade S Samowitz. (2011) Epidermal Growth Factor Receptor Pathway Mutations and Colorectal Cancer Therapy. Archives of Pathology & Laboratory Medicine 135:10, 1278-1282
CrossRef96
Antonio T Baines, Dapeng Xu, Channing J Der. (2011) Inhibition of Ras for cancer treatment: the search continues. Future Medicinal Chemistry 3:14, 1787-1808
CrossRef97
Pamela Jo Harris, Keith C Bible. (2011) Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches. Expert Opinion on Investigational Drugs 20:10, 1357-1375
CrossRef98
Nicolas Dumaz, Martine Bagot, Armand Bensussan. (2011) Quand CRAF remplace BRAF dans le mélanome. médecine/sciences 27:10, 817-819
CrossRef99
A. K. Tiwari, H. K. Roy. (2011) Progress against cancer (1971-2011): how far have we come?. Journal of Internal Medicineno-no
CrossRef100
Christian U. Blank, Anna I. Hooijkaas, John B. Haanen, Ton N. Schumacher. (2011) Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunology, Immunotherapy 60:10, 1359-1371
CrossRef101
Dimitrios H Roukos. (2011) Cancer genome sequencing and functional genomics: from translational to clinical medicine. Pharmacogenomics 12:10, 1371-1374
CrossRef102
Stewart Bates. (2011) The role of gene expression profiling in drug discovery. Current Opinion in Pharmacology 11:5, 549-556
CrossRef103
Pablo Lopez-Bergami. (2011) The role of mitogen- and stress-activated protein kinase pathways in melanoma. Pigment Cell & Melanoma Research 24:5, 902-921
CrossRef104
Zeynep Eroglu, Kevin M. Kong, James G. Jakowatz, Wolfram Samlowski, John P. Fruehauf. (2011) Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma. Cancer Chemotherapy and Pharmacology 68:4, 1081-1087
CrossRef105
Hwangseo Park, Hwanho Choi, Seunghee Hong, Sungwoo Hong. (2011) Identification of novel BRAF kinase inhibitors with structure-based virtual screening. Bioorganic & Medicinal Chemistry Letters 21:19, 5753-5756
CrossRef106
Roger Mouawad, Jean-Philippe Spano, David Khayat. (2011) Are we entering a new era in melanoma treatment? Lesson from ASCO 2011. Melanoma Research 21:5, 377-379
CrossRef107
Sarah Francoz, Pierre Dubus. (2011) CRAF, acteur-clé dans les adénocarcinomes pulmonaires induits par l’oncogène K-Ras. médecine/sciences 27:10, 820-822
CrossRef108
Thomas I. Peng Soh, Wei Peng Yong, Federico Innocenti. (2011) Review: Recent progress and clinical importance on pharmacogenetics in cancer therapy. Clinical Chemistry and Laboratory Medicine---
CrossRef109
K J Basile, E V Abel, A E Aplin. (2011) Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene
CrossRef110
Todd D Prickett, Xiaomu Wei, Isabel Cardenas-Navia, Jamie K Teer, Jimmy C Lin, Vijay Walia, Jared Gartner, Jiji Jiang, Praveen F Cherukuri, Alfredo Molinolo, Michael A Davies, Jeffrey E Gershenwald, Katherine Stemke-Hale, Steven A Rosenberg, Elliott H Margulies, Yardena Samuels. (2011) Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nature Genetics 43:11, 1119-1126
CrossRef111
Markus K Muellner, Iris Z Uras, Bianca V Gapp, Claudia Kerzendorfer, Michal Smida, Hannelore Lechtermann, Nils Craig-Mueller, Jacques Colinge, Gerhard Duernberger, Sebastian M B Nijman. (2011) A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nature Chemical Biology 7:11, 787-793
CrossRef112
Nilay Sethi, Yibin Kang. (2011) Unravelling the complexity of metastasis — molecular understanding and targeted therapies. Nature Reviews Cancer 11:10, 735-748
CrossRef113
Feero, W. Gregory, Guttmacher, Alan E., , Hudson, Kathy L., . (2011) Genomics, Health Care, and Society. New England Journal of Medicine 365:11, 1033-1041
Full Text114
Jatinder Goyal, Evan J. Lipson, Neda Rezaee, Barish H. Edil, Rich Schulick, Christopher L. Wolfgang, Ralph H. Hruban, Emmanuel S. Antonarakis. (2011) Surgical Resection of Malignant Melanoma Metastatic to the Pancreas: Case Series and Review of Literature. Journal of Gastrointestinal Cancer
CrossRef115
Sebastian Blanck, Thomas Cruchter, Adina Vultur, Radostan Riedel, Klaus Harms, Meenhard Herlyn, Eric Meggers. (2011) Organometallic Pyridylnaphthalimide Complexes as Protein Kinase Inhibitors. Organometallics 30:17, 4598-4606
CrossRef116
H A Tawbi, L Villaruz, A Tarhini, S Moschos, M Sulecki, F Viverette, J Shipe-Spotloe, R Radkowski, J M Kirkwood. (2011) Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours. British Journal of Cancer 105:6, 773-777
CrossRef117
S S Ganguly, L S Fiore, J T Sims, J W Friend, D Srinivasan, M A Thacker, M L Cibull, C Wang, M Novak, D M Kaetzel, R Plattner. (2011) c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression. Oncogene
CrossRef118
Emanuela Romano, Gary K Schwartz, Paul B Chapman, Jedd D Wolchock, Richard D Carvajal. (2011) Treatment implications of the emerging molecular classification system for melanoma. The Lancet Oncology 12:9, 913-922
CrossRef119
C. Hafner. (2011) Therapie des metastasierten Melanoms mit BRAF-Inhibitoren. Der Hautarzt 62:9, 696-698
CrossRef120
Steve Wenglowsky, Kateri A. Ahrendt, Alex J. Buckmelter, Bainian Feng, Susan L. Gloor, Stefan Gradl, Jonas Grina, Joshua D. Hansen, Ellen R. Laird, Paul Lunghofer, Simon Mathieu, David Moreno, Brad Newhouse, Li Ren, Tyler Risom, Joachim Rudolph, Jeongbeob Seo, Hillary L. Sturgis, Walter C. Voegtli, Zhaoyang Wen. (2011) Pyrazolopyridine inhibitors of B-RafV600E. Part 2: Structure–activity relationships. Bioorganic & Medicinal Chemistry Letters 21:18, 5533-5537
CrossRef121
Alexander M.M. Eggermont, Caroline Robert. (2011) New drugs in melanoma: It’s a whole new world. European Journal of Cancer 47:14, 2150-2157
CrossRef122
Dana B. Cardin, Jordan D. Berlin. (2011) Drugs on the Horizon for Colorectal Cancer. Current Colorectal Cancer Reports 7:3, 191-199
CrossRef123
Andrew E Aplin, Fred M Kaplan, Yongping Shao. (2011) Mechanisms of Resistance to RAF Inhibitors in Melanoma. Journal of Investigative Dermatology 131:9, 1817-1820
CrossRef124
Dimosthenis E Ziogas, Dimitrios H Roukos. (2011) Genome diagnostics: next-generation sequencing, new genome-wide association studies and clinical challenges. Expert Review of Molecular Diagnostics 11:7, 663-666
CrossRef125
Alberto Fusi, Rebecca Berdel, Swantje Havemann, Anika Nonnenmacher, Ulrich Keilholz. (2011) Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity. European Journal of Cancer 47:13, 1971-1976
CrossRef126
Filip Janku, Ignacio Garrido-Laguna, Lubos B. Petruzelka, David J. Stewart, Razelle Kurzrock. (2011) Novel Therapeutic Targets in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:9, 1601-1612
CrossRef127
Teofila Seremet, Francis Brasseur, Pierre G. Coulie. (2011) Tumor-Specific Antigens and Immunologic Adjuvants in Cancer Immunotherapy. The Cancer Journal 17:5, 325-330
CrossRef128
Carol Beadling, Michael C. Heinrich, Andrea Warrick, Erin M. Forbes, Dylan Nelson, Emily Justusson, Judith Levine, Tanaya L. Neff, Janice Patterson, Ajia Presnell, Arin McKinley, Laura J. Winter, Christie Dewey, Amy Harlow, Oscar Barney, Brian J. Druker, Kathryn G. Schuff, Christopher L. Corless. (2011) Multiplex Mutation Screening by Mass Spectrometry. The Journal of Molecular Diagnostics 13:5, 504-513
CrossRef129
Ahmad Jalili, Anna Moser, Mikhail Pashenkov, Christine Wagner, Gaurav Pathria, Viola Borgdorff, Melanie Gschaider, Georg Stingl, Sridhar Ramaswamy, Stephan N Wagner. (2011) Polo-Like Kinase 1 Is a Potential Therapeutic Target in Human Melanoma. Journal of Investigative Dermatology 131:9, 1886-1895
CrossRef130
Jan P. Deroose, Alexander M. M. Eggermont, Albertus N. Geel, Johannes H. W. Wilt, Jacobus W. A. Burger, Cornelis Verhoef. (2011) 20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters. Annals of Surgical Oncology
CrossRef131
Vinod P Balachandran, Michael J Cavnar, Shan Zeng, Zubin M Bamboat, Lee M Ocuin, Hebroon Obaid, Eric C Sorenson, Rachel Popow, Charlotte Ariyan, Ferdinand Rossi, Peter Besmer, Tianhua Guo, Cristina R Antonescu, Takahiro Taguchi, Jianda Yuan, Jedd D Wolchok, James P Allison, Ronald P DeMatteo. (2011) Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nature Medicine 17:9, 1094-1100
CrossRef132
C. Albers, A. L. Illert, C. Miething, H. Leischner, M. Thiede, C. Peschel, J. Duyster. (2011) An RNAi-based system for loss-of-function analysis identifies Raf1 as a crucial mediator of BCR-ABL-driven leukemogenesis. Blood 118:8, 2200-2210
CrossRef133
Nicholas B. La Thangue, David J. Kerr. (2011) Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nature Reviews Clinical Oncology 8:10, 587-596
CrossRef134
Matti L. Gild, Martyn Bullock, Bruce G. Robinson, Roderick Clifton-Bligh. (2011) Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nature Reviews Endocrinology 7:10, 617-624
CrossRef135
S. Kruijff, E. Bastiaannet, A. H. Brouwers, W. B. Nagengast, M. J. Speijers, A. J. H. Suurmeijer, G. A. Hospers, H. J. Hoekstra. (2011) Use of S-100B to Evaluate Therapy Effects during Bevacizumab Induction Treatment in AJCC Stage III Melanoma. Annals of Surgical Oncology
CrossRef136
R. W. Humphrey, L. M. Brockway-Lunardi, D. T. Bonk, K. M. Dohoney, J. H. Doroshow, S. J. Meech, M. J. Ratain, S. L. Topalian, D. M. Pardoll. (2011) Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer. JNCI Journal of the National Cancer Institute 103:16, 1222-1226
CrossRef137
G Maurer, B Tarkowski, M Baccarini. (2011) Raf kinases in cancer–roles and therapeutic opportunities. Oncogene 30:32, 3477-3488
CrossRef138
Ignacio Garrido-Laguna, Manuel Hidalgo, Razelle Kurzrock. (2011) The inverted pyramid of biomarker-driven trials. Nature Reviews Clinical Oncology 8:9, 562-566
CrossRef139
Rahat Noor, Van A Trinh, Kevin B Kim, Wen-Jen Hwu. (2011) BRAF-targeted therapy for metastatic melanoma: rationale, clinical activity and safety. Clinical Investigation 1:8, 1127-1139
CrossRef140
Richard Simon. (2011) Genomic biomarkers in predictive medicine. An interim analysis. EMBO Molecular Medicine 3:8, 429-435
CrossRef141
Sandra Medic, Helen Rizos, Mel Ziman. (2011) Differential PAX3 functions in normal skin melanocytes and melanoma cells. Biochemical and Biophysical Research Communications 411:4, 832-837
CrossRef142
Sapna P. Patel, Kevin B. Kim, Nicholas E. Papadopoulos, Wen-Jen Hwu, Patrick Hwu, Victor G. Prieto, Menashe Bar-Eli, Maya Zigler, Andrey Dobroff, Yulia Bronstein, Roland L. Bassett, Anna G. Vardeleon, Agop Y. Bedikian. (2011) A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Research 21:4, 357-363
CrossRef143
Yongmei Feng, Elisa Barile, Surya K. De, John L. Stebbins, Apple Cortez, Pedro Aza-Blanc, Jessie Villanueva, Meenhard Heryln, Stan Krajewski, Maurizio Pellecchia, Ze’ev A. Ronai, Gary G. Chiang. (2011) Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-κB pathways. Pigment Cell & Melanoma Research 24:4, 703-713
CrossRef144
Inna V. Fedorenko, Kim H.T. Paraiso, Keiran S.M. Smalley. (2011) Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochemical Pharmacology 82:3, 201-209
CrossRef145
W. Joost Lesterhuis, John B. A. G. Haanen, Cornelis J. A. Punt. (2011) Cancer immunotherapy – revisited. Nature Reviews Drug Discovery 10:8, 591-600
CrossRef146
Antonio Carlos Buzaid, Rafael Aron Schmerling, Rodrigo Antonio Vieira Guedes, Daniela de Freitas, William Nassib William. (2011) High-dose interleukin-2 in patients with metastatic melanoma whose disease progressed after biochemotherapy. Melanoma Research 21:4, 370-375
CrossRef147
Jonathan L Curry, Gerald S Falchook, Carlos A Torres-Cabala, Michael T Tetzlaff, Victor G Prieto. (2011) Resistant mechanisms to BRAF inhibitor PLX4032 in melanoma. Expert Review of Dermatology 6:4, 355-357
CrossRef148
Maurie Markman. (2011) Information Overload in Oncology Practice and its Potential Negative Impact on the Delivery of Optimal Patient Care. Current Oncology Reports 13:4, 249-251
CrossRef149
Chris Thompson, Stephen Leong, Wells Messersmith. (2011) Promising Targets and Drugs in Development for Colorectal Cancer. Seminars in Oncology 38:4, 588-597
CrossRef150
Christos S Katsios, Dimosthenis E Ziogas, Dimitrios H Roukos. (2011) Pharmacogenomics for tailoring cardiovascular and anticancer drugs: from genotyping to whole-genome sequencing. Pharmacogenomics 12:8, 1081-1085
CrossRef151
Ling Yu, Elvira Favoino, Yangyang Wang, Yang Ma, Xiaojuan Deng, Xinhui Wang. (2011) The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells. Immunologic Research 50:2-3, 294-302
CrossRef152
Ingo K. Mellinghoff, Andrew B. Lassman, Patrick Y. Wen. (2011) Signal transduction inhibitors and antiangiogenic therapies for malignant glioma. Glia 59:8, 1205-1212
CrossRef153
Haim Gavriel, Grant McArthur, Andrew Sizeland, Michael Henderson. (2011) Review. Melanoma Research 21:4, 257-266
CrossRef154
Bianca Devitt, Wendy Liu, Renato Salemi, Rory Wolfe, John Kelly, Chin-Yuan Tzen, Alexander Dobrovic, Grant McArthur. (2011) Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell & Melanoma Research 24:4, 666-672
CrossRef155
H. W. Cheung, G. S. Cowley, B. A. Weir, J. S. Boehm, S. Rusin, J. A. Scott, A. East, L. D. Ali, P. H. Lizotte, T. C. Wong, G. Jiang, J. Hsiao, C. H. Mermel, G. Getz, J. Barretina, S. Gopal, P. Tamayo, J. Gould, A. Tsherniak, N. Stransky, B. Luo, Y. Ren, R. Drapkin, S. N. Bhatia, J. P. Mesirov, L. A. Garraway, M. Meyerson, E. S. Lander, D. E. Root, W. C. Hahn. (2011) Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proceedings of the National Academy of Sciences 108:30, 12372-12377
CrossRef156
T Eisen, R Marais, A Affolter, P Lorigan, C Robert, P Corrie, C Ottensmeier, C Chevreau, D Chao, P D Nathan, T Jouary, M Harries, S Negrier, E Montegriffo, T Ahmad, I Gibbens, M G James, U P Strauss, S Prendergast, M E Gore. (2011) Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. British Journal of Cancer 105:3, 353-359
CrossRef157
Fang-Yu Lin, Yufeng J. Tseng. (2011) Structure-Based Fragment Hopping for Lead Optimization Using Predocked Fragment Database. Journal of Chemical Information and Modeling 51:7, 1703-1715
CrossRef158
M. R. Sharma, W. M. Stadler, M. J. Ratain. (2011) Randomized Phase II Trials: A Long-term Investment With Promising Returns. JNCI Journal of the National Cancer Institute 103:14, 1093-1100
CrossRef159
Adam L Cohen, Raffaella Soldi, Haiyu Zhang, Adam M Gustafson, Ryan Wilcox, Bryan E Welm, Jeffrey T Chang, Evan Johnson, Avrum Spira, Stefanie S Jeffrey, Andrea H Bild. (2011) A pharmacogenomic method for individualized prediction of drug sensitivity. Molecular Systems Biology 7,
CrossRef160
Barry S. Taylor, Jordi Barretina, Robert G. Maki, Cristina R. Antonescu, Samuel Singer, Marc Ladanyi. (2011) Advances in sarcoma genomics and new therapeutic targets. Nature Reviews Cancer 11:8, 541-557
CrossRef161
L Sigalotti, E Fratta, G Parisi, S Coral, M Maio. (2011) Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?. British Journal of Cancer 105:2, 327-328
CrossRef162
F Xing, Y Persaud, C A Pratilas, B S Taylor, M Janakiraman, Q-B She, H Gallardo, C Liu, T Merghoub, B Hefter, I Dolgalev, A Viale, A Heguy, E De Stanchina, D Cobrinik, G Bollag, J Wolchok, A Houghton, D B Solit. (2011) Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF. Oncogene
CrossRef163
David Capper, Matthias Preusser, Antje Habel, Felix Sahm, Ulrike Ackermann, Genevieve Schindler, Stefan Pusch, Gunhild Mechtersheimer, Hanswalter Zentgraf, Andreas Deimling. (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathologica 122:1, 11-19
CrossRef164
Michael E Ming. (2011) The Search for a Chemoprevention Agent Effective against Melanoma: Considerations and Challenges. Journal of Investigative Dermatology 131:7, 1401-1403
CrossRef165
Jaclyn C. Flanigan, Lucia B. Jilaveanu, Mark Faries, Mario Sznol, Stephan Ariyan, James B. Yu, Jonathan P.S. Knisely, Veronica L. Chiang, Harriet M. Kluger. (2011) Melanoma Brain Metastases: Is It Time to Reassess the Bias?. Current Problems in Cancer 35:4, 200-210
CrossRef166
Kian-Ngiap Chua, Kar Lai Poon, Jormay Lim, Wen-Jing Sim, Ruby Yun-Ju Huang, Jean Paul Thiery. (2011) Target cell movement in tumor and cardiovascular diseases based on the epithelial–mesenchymal transition concept. Advanced Drug Delivery Reviews 63:8, 558-567
CrossRef167
Niloufer Khan, Mohammad K. Khan, Alex Almasan, Arun D. Singh, Roger Macklis. (2011) The Evolving Role of Radiation Therapy in the Management of Malignant Melanoma. International Journal of Radiation Oncology*Biology*Physics 80:3, 645-654
CrossRef168
Karli Rosner. (2011) DNase1: a new personalized therapy for cancer?. Expert Review of Anticancer Therapy 11:7, 983-986
CrossRef169
Miguel A. Materin, Mark Faries, Harriet M. Kluger. (2011) Molecular Alternations in Uveal Melanoma. Current Problems in Cancer 35:4, 211-224
CrossRef170
Laura Held, Thomas K. Eigentler, Friedegund Meier, Marko Held, Martin Röcken, Claus Garbe, Jürgen Bauer. (2011) Oncogenetics of melanoma: basis for molecular diagnostics and therapy. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 9:7, 510-516
CrossRef171
Alexander Picker, David B Jackson. (2011) Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine. Expert Review of Molecular Diagnostics 11:6, 567-577
CrossRef172
Nagendra Natarajan, Sucheta Telang, Donald Miller, Jason Chesney. (2011) Novel Immunotherapeutic Agents and Small Molecule Antagonists of Signalling Kinases for the Treatment of Metastatic Melanoma. Drugs 71:10, 1233-1250
CrossRef173
Katayoon Kasaian, Steven JM Jones. (2011) A new frontier in personalized cancer therapy: mapping molecular changes. Future Oncology 7:7, 873-894
CrossRef174
Edward Chu. (2011) An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer. Clinical Colorectal Cancer
CrossRef175
Ernstoff, Marc S., . (2011) Been There, Not Done That — Melanoma in the Age of Molecular Therapy. New England Journal of Medicine 364:26, 2547-2548
Full Text176
Chapman, Paul B., Hauschild, Axel, Robert, Caroline, Haanen, John B., Ascierto, Paolo, Larkin, James, Dummer, Reinhard, Garbe, Claus, Testori, Alessandro, Maio, Michele, Hogg, David, Lorigan, Paul, Lebbe, Celeste, Jouary, Thomas, Schadendorf, Dirk, Ribas, Antoni, O'Day, Steven J., Sosman, Jeffrey A., Kirkwood, John M., Eggermont, Alexander M.M., Dreno, Brigitte, Nolop, Keith, Li, Jiang, Nelson, Betty, Hou, Jeannie, Lee, Richard J., Flaherty, Keith T., McArthur, and Grant A., . (2011) Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. New England Journal of Medicine 364:26, 2507-2516
Full Text177
M. A. Sukhai, P. A. Spagnuolo, S. Weir, J. Kasper, L. Patton, A. D. Schimmer. (2011) New sources of drugs for hematologic malignancies. Blood 117:25, 6747-6755
CrossRef178
Tiacci, Enrico, Trifonov, Vladimir, Schiavoni, Gianluca, Holmes, Antony, Kern, Wolfgang, Martelli, Maria Paola, Pucciarini, Alessandra, Bigerna, Barbara, Pacini, Roberta, Wells, Victoria A., Sportoletti, Paolo, Pettirossi, Valentina, Mannucci, Roberta, Elliott, Oliver, Liso, Arcangelo, Ambrosetti, Achille, Pulsoni, Alessandro, Forconi, Francesco, Trentin, Livio, Semenzato, Gianpietro, Inghirami, Giorgio, Capponi, Monia, Di Raimondo, Francesco, Patti, Caterina, Arcaini, Luca, Musto, Pellegrino, Pileri, Stefano, Haferlach, Claudia, Schnittger, Susanne, Pizzolo, Giovanni, Foà, Robin, Farinelli, Laurent, Haferlach, Torsten, Pasqualucci, Laura, Rabadan, Raul, Falini, Brunangelo, . (2011) BRAF Mutations in Hairy-Cell Leukemia. New England Journal of Medicine 364:24, 2305-2315
Full Text179
Jennifer A. Freedman, Douglas S. Tyler, Joseph R. Nevins, Christina K. Augustine. (2011) Use of Gene Expression and Pathway Signatures to Characterize the Complexity of Human Melanoma. The American Journal of Pathology 178:6, 2513-2522
CrossRef180
N. Suwaki, E. Vanhecke, K. M. Atkins, M. Graf, K. Swabey, P. Huang, P. Schraml, H. Moch, A. M. Cassidy, D. Brewer, B. Al-Lazikani, P. Workman, J. De-Bono, S. B. Kaye, J. Larkin, M. E. Gore, C. L. Sawyers, P. Nelson, T. M. Beer, H. Geng, L. Gao, D. Z. Qian, J. J. Alumkal, G. Thomas, G. V. Thomas. (2011) A HIF-Regulated VHL-PTP1B-Src Signaling Axis Identifies a Therapeutic Target in Renal Cell Carcinoma. Science Translational Medicine 3:85, 85ra47-85ra47
CrossRef181
Jack L Arbiser, David E Fisher. (2011) Fisetin: A Natural Fist against Melanoma?. Journal of Investigative Dermatology 131:6, 1187-1189
CrossRef182
David J. Easty, Steven G. Gray, Kenneth J. O’Byrne, Dearbhaile O’Donnell, Dorothy C. Bennett. (2011) Receptor tyrosine kinases and their activation in melanoma. Pigment Cell & Melanoma Research 24:3, 446-461
CrossRef183
Konstantinos Linos, Andrzej Slominski, Jeffrey S Ross, J Andrew Carlson. (2011) Melanoma update: diagnostic and prognostic factors that can effectively shape and personalize management. Biomarkers in Medicine 5:3, 333-360
CrossRef184
Jean-Étienne Morlighem, Matthias Harbers, Jan Traeger-Synodinos, Alexander Lezhava. (2011) DNA amplification techniques in pharmacogenomics. Pharmacogenomics 12:6, 845-860
CrossRef185
Savithri Ramurthy, Mina Aikawa, Payman Amiri, Abran Costales, Ahmad Hashash, Johanna M. Jansen, Song Lin, Sylvia Ma, Paul A. Renhowe, Cynthia M. Shafer, Sharadha Subramanian, Leonard Sung, Joelle Verhagen. (2011) Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 21:11, 3286-3289
CrossRef186
J. Vaubel, D. Schadendorf. (2011) Moderne Pharmakotherapie des malignen Melanoms. Der Internist 52:6, 756-764
CrossRef187
Michelle C. Mendoza, E. Emrah Er, John Blenis. (2011) The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends in Biochemical Sciences 36:6, 320-328
CrossRef188
Hikmat A Al-Ahmadie, Gopa Iyer, Manickam Janakiraman, Oscar Lin, Adriana Heguy, Satish K. Tickoo, Samson W. Fine, Anuradha Gopalan, Ying-bei Chen, Arjun Balar, Jamie Riches, Bernard Bochner, Guido Dalbagni, Dean F. Bajorin, Victor E. Reuter, Matthew I. Milowsky, David B. Solit. (2011) Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. The Journal of Pathology 224:2, 270-279
CrossRef189
S. Ugurel, J.C. Becker. (2011) Therapie des inoperabel metastasierten Melanoms. Der Hautarzt 62:6, 423-429
CrossRef190
Heidi Schwarzenbach, Dave S. B. Hoon, Klaus Pantel. (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nature Reviews Cancer 11:6, 426-437
CrossRef191
Vernon K. Sondak, Keiran S. M. Smalley, Ragini Kudchadkar, Seden Grippon, Peter Kirkpatrick. (2011) Ipilimumab. Nature Reviews Drug Discovery 10:6, 411-412
CrossRef192
Oliver Klein, Christopher Schmidt, Ashley Knights, Ian D Davis, Weisan Chen, Jonathan Cebon. (2011) Melanoma vaccines: developments over the past 10 years. Expert Review of Vaccines 10:6, 853-873
CrossRef193
B. Kovach, R. Langland, R. Schilling, H. Halait, S. Anderson, K. Bloom, D.U. Vallera, J. Rueschoff, H.J. Lawrence. (2011) CO18. The analytic performance of the cobasR 4800 BRAF V600 Mutation Test in the detection of V600E mutations in malignant melanoma. Melanoma Research 21, e11
CrossRef194
Antoni Ribas, Keith T. Flaherty. (2011) BRAF targeted therapy changes the treatment paradigm in melanoma. Nature Reviews Clinical Oncology 8:7, 426-433
CrossRef195
Katherine A. Rauen, Anuradha Banerjee, W. Robert Bishop, Jennifer O. Lauchle, Frank McCormick, Martin McMahon, Teri Melese, Pamela N. Munster, Sorena Nadaf, Roger J. Packer, Judith Sebolt-Leopold, David H. Viskochil. (2011) Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. American Journal of Medical Genetics Part C: Seminars in Medical Genetics 157:2, 136-146
CrossRef196
Steve Wenglowsky, Li Ren, Kateri A. Ahrendt, Ellen R. Laird, Ignacio Aliagas, Bruno Alicke, Alex J. Buckmelter, Edna F. Choo, Victoria Dinkel, Bainian Feng, Susan L. Gloor, Stephen E. Gould, Stefan Gross, Janet Gunzner-Toste, Joshua D. Hansen, Georgia Hatzivassiliou, Bonnie Liu, Kim Malesky, Simon Mathieu, Brad Newhouse, Nicholas J. Raddatz, Yingqing Ran, Sumeet Rana, Nikole Randolph, Tyler Risom, Joachim Rudolph, Scott Savage, LeAnn T. Selby, Michael Shrag, Kyung Song, Hillary L. Sturgis, Walter C. Voegtli, Zhaoyang Wen, Brandon S. Willis, Richard D. Woessner, Wen-I Wu, Wendy B. Young, Jonas Grina. (2011) Pyrazolopyridine Inhibitors of B-Raf V600E . Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors. ACS Medicinal Chemistry Letters 2:5, 342-347
CrossRef197
R. Katayama, T. M. Khan, C. Benes, E. Lifshits, H. Ebi, V. M. Rivera, W. C. Shakespeare, A. J. Iafrate, J. A. Engelman, A. T. Shaw. (2011) Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proceedings of the National Academy of Sciences 108:18, 7535-7540
CrossRef198
Rafael B. Blasco, Sarah Francoz, David Santamaría, Marta Cañamero, Pierre Dubus, Jean Charron, Manuela Baccarini, Mariano Barbacid. (2011) c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma. Cancer Cell 19:5, 652-663
CrossRef199
Eric Lau, Ze'ev Ronai. (2011) RAF-isotype switching: from B to C through PDE. Nature Structural & Molecular Biology 18:5, 517-518
CrossRef200
Curt Peterson. (2011) Drug therapy of cancer. European Journal of Clinical Pharmacology 67:5, 437-447
CrossRef201
Glen M Boyle. (2011) Therapy for metastatic melanoma: an overview and update. Expert Review of Anticancer Therapy 11:5, 725-737
CrossRef202
Augusto Villanueva, Josep M. Llovet. (2011) Targeted Therapies for Hepatocellular Carcinoma. Gastroenterology 140:5, 1410-1426
CrossRef203
Florastina Payton, Rumu Bose, William L. Alworth, Addanki P. Kumar, Rita Ghosh. (2011) 4-Methylcatechol-induced oxidative stress induces intrinsic apoptotic pathway in metastatic melanoma cells. Biochemical Pharmacology 81:10, 1211-1218
CrossRef204
Seunghee Hong, Sungwoo Hong. (2011) Overcoming metastatic melanoma with BRAF inhibitors. Archives of Pharmacal Research 34:5, 699-701
CrossRef205
Stanley P.L. Leong, Jeffrey E. Gershenwald, Seng-jaw Soong, Dirk Schadendorf, Ahmad A. Tarhini, Sanjiv Agarwala, Axel Hauschild, Christopher W.M. Soon, Adil Daud, Mohammed Kashani-Sabet. (2011) Cutaneous melanoma: A model to study cancer metastasis. Journal of Surgical Oncology 103:6, 538-549
CrossRef206
Yoshinari Asaoka, Tsuneo Ikenoue, Kazuhiko Koike. (2011) New targeted therapies for gastric cancer. Expert Opinion on Investigational Drugs 20:5, 595-604
CrossRef207
Adi F. Gazdar. (2011) Tyrosine Kinase Inhibitors and Epidermal Growth Factor Receptor (EGFR) Mutations in Non-Small Cell Lung Cancer. Medicine 90:3, 168-170
CrossRef208
Pierre Mordant, Yohann Loriot, Benoît Lahon, Yves Castier, Guy Lesèche, Jean-Charles Soria, Christophe Massard, Eric Deutsch. (2011) Minimal residual disease in solid neoplasia: New frontier or red-herring?. Cancer Treatment Reviews
CrossRef209
Lauren Martz. (2011) New players in melanoma. Science-Business eXchange 4:15,
CrossRef210
April F. Eichler, Euiheon Chung, David P. Kodack, Jay S. Loeffler, Dai Fukumura, Rakesh K. Jain. (2011) The biology of brain metastases—translation to new therapies. Nature Reviews Clinical Oncology
CrossRef211
Rajasekharan Somasundaram, Jessie Villanueva, Meenhard Herlyn. (2011) Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?. Molecular Therapy 19:4, 638-640
CrossRef212
Martin McMahon. (2011) Parsing out the complexity of RAF inhibitor resistance. Pigment Cell & Melanoma Research 24:2, 361-365
CrossRef213
Iris Helfrich, Dirk Schadendorf. (2011) Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: One step forward for overcoming anti-angiogenic drug resistance?. Molecular Oncology 5:2, 137-149
CrossRef214
A. Ireland, M. Millward, R. Pearce, M. Lee, M. Ziman. (2011) Genetic factors in metastatic progression of cutaneous melanoma: the future role of circulating melanoma cells in prognosis and management. Clinical & Experimental Metastasis 28:4, 327-336
CrossRef215
Alan Spatz, Alexander M.M. Eggermont. (2011) Melanoma – The pieces of the puzzle finally start coming together!. Molecular Oncology 5:2, 113-115
CrossRef216
Klaus G Griewank, Rajmohan Murali, Thomas Wiesner, Boris C Bastian. (2011) Genetic alterations in uveal melanoma. Expert Review of Ophthalmology 6:2, 129-132
CrossRef217
Richard A. Scolyer, Georgina V. Long, John F. Thompson. (2011) Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Molecular Oncology 5:2, 124-136
CrossRef218
Angus J.M. Cameron. (2011) Occupational hazards: allosteric regulation of protein kinases through the nucleotide-binding pocket. Biochemical Society Transactions 39:2, 472-476
CrossRef219
Shankar Balasubramanian, Laurence H. Hurley, Stephen Neidle. (2011) Targeting G-quadruplexes in gene promoters: a novel anticancer strategy?. Nature Reviews Drug Discovery 10:4, 261-275
CrossRef220
Mark Shackleton. (2011) Pulling RANK: Are Some Melanoma Cells More Malignant than Others?. Journal of Investigative Dermatology 131:4, 814-816
CrossRef221
Thomas F Gajewski, Mercedes Fuertes, Robbert Spaapen, Yan Zheng, Justin Kline. (2011) Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Current Opinion in Immunology 23:2, 286-292
CrossRef222
Elizabeth A Guancial, Dipanjan Chowdhury, Jonathan E Rosenberg. (2011) Personalized therapy for urothelial cancer: review of the clinical evidence. Clinical Investigation 1:4, 543-555
CrossRef223
Daniel A. Haber, Nathanael S. Gray, Jose Baselga. (2011) The Evolving War on Cancer. Cell 145:1, 19-24
CrossRef224
Marie C. Zipser, Ossia M. Eichhoff, Daniel S. Widmer, Natalie C. Schlegel, Nicola L. Schoenewolf, Darrin Stuart, Weihua Liu, Humphrey Gardner, Paul D. Smith, Paolo Nuciforo, Reinhard Dummer, Keith S. Hoek. (2011) A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status. Pigment Cell & Melanoma Research 24:2, 326-333
CrossRef225
Thomas F. Gajewski. (2011) Molecular Profiling of Melanoma and the Evolution of Patient-Specific Therapy. Seminars in Oncology 38:2, 236-242
CrossRef226
Thomas Stricker, Daniel V.T. Catenacci, Tanguy Y. Seiwert. (2011) Molecular Profiling of Cancer—The Future of Personalized Cancer Medicine: A Primer on Cancer Biology and the Tools Necessary to Bring Molecular Testing to the Clinic. Seminars in Oncology 38:2, 173-185
CrossRef227
Igor Puzanov, Patrick Burnett, Keith T. Flaherty. (2011) Biological challenges of BRAF inhibitor therapy. Molecular Oncology 5:2, 116-123
CrossRef228
M. R. Stratton. (2011) Exploring the Genomes of Cancer Cells: Progress and Promise. Science 331:6024, 1553-1558
CrossRef229
Feero, W. Gregory, Guttmacher, Alan E., , Wang, Liewei, McLeod, Howard L., Weinshilboum, Richard M., . (2011) Genomics and Drug Response. New England Journal of Medicine 364:12, 1144-1153
Full Text230
Chabner, Bruce A., . (2011) Early Accelerated Approval for Highly Targeted Cancer Drugs. New England Journal of Medicine 364:12, 1087-1089
Full Text231
Richard Mark White, Jennifer Cech, Sutheera Ratanasirintrawoot, Charles Y. Lin, Peter B. Rahl, Christopher J. Burke, Erin Langdon, Matthew L. Tomlinson, Jack Mosher, Charles Kaufman, Frank Chen, Hannah K. Long, Martin Kramer, Sumon Datta, Donna Neuberg, Scott Granter, Richard A. Young, Sean Morrison, Grant N. Wheeler, Leonard I. Zon. (2011) DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 471:7339, 518-522
CrossRef232
R. L. Schilsky. (2011) Accrual to Cancer Clinical Trials in the Era of Molecular Medicine. Science Translational Medicine 3:75, 75cm9-75cm9
CrossRef233
J. Urosevic, V. Sauzeau, M. L. Soto-Montenegro, S. Reig, M. Desco, E. M. B. Wright, M. Canamero, F. Mulero, S. Ortega, X. R. Bustelo, M. Barbacid. (2011) Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome. Proceedings of the National Academy of Sciences 108:12, 5015-5020
CrossRef234
Mario Sznol. (2011) Molecular Markers of Response to Treatment for Melanoma. The Cancer Journal 17:2, 127-133
CrossRef235
Tomonori Yaguchi, Hidetoshi Sumimoto, Chie Kudo-Saito, Nobuo Tsukamoto, Ryo Ueda, Tomoko Iwata-Kajihara, Hiroshi Nishio, Naoshi Kawamura, Yutaka Kawakami. (2011) The mechanisms of cancer immunoescape and development of overcoming strategies. International Journal of Hematology 93:3, 294-300
CrossRef236
Dana Pe'er, Nir Hacohen. (2011) Principles and Strategies for Developing Network Models in Cancer. Cell 144:6, 864-873
CrossRef237
Shawn G Kwatra. (2011) Targeting X-Linked Inhibitor of Apoptosis Protein for Melanoma Therapy: The Need for More Homogeneous Samples and the Importance of Cell Lines. Journal of Investigative Dermatology 131:3, 797-797
CrossRef238
Ian J Majewski, René Bernards. (2011) Taming the dragon: genomic biomarkers to individualize the treatment of cancer. Nature Medicine304-312
CrossRef239
Dimitrios H Roukos. (2011) PLX4032 and melanoma: resistance, expectations and uncertainty. Expert Review of Anticancer Therapy 11:3, 325-328
CrossRef240
Zenta Walther, Jeffrey Sklar. (2011) Molecular Tumor Profiling for Prediction of Response to Anticancer Therapies. The Cancer Journal 17:2, 71-79
CrossRef241
Maria J. Sambade, Eldon C. Peters, Nancy E. Thomas, William K. Kaufmann, Randall J. Kimple, Janiel M. Shields. (2011) Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiotherapy and Oncology 98:3, 394-399
CrossRef242
Lynda Chin, Jannik N Andersen, P Andrew Futreal. (2011) Cancer genomics: from discovery science to personalized medicine. Nature Medicine 17:3, 297-303
CrossRef243
Caitriona Ryan, Anne Bowcock, Alan Menter. (2011) Use of pharmacogenomics in psoriasis. Clinical Investigation 1:3, 399-411
CrossRef244
Genevieve Schindler, David Capper, Jochen Meyer, Wibke Janzarik, Heymut Omran, Christel Herold-Mende, Kirsten Schmieder, Pieter Wesseling, Christian Mawrin, Martin Hasselblatt, David N. Louis, Andrey Korshunov, Stefan Pfister, Christian Hartmann, Werner Paulus, Guido Reifenberger, Andreas Deimling. (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathologica 121:3, 397-405
CrossRef245
Caroline Robert, Jean-Philippe Arnault, Christine Mateus. (2011) RAF inhibition and induction of cutaneous squamous cell carcinoma. Current Opinion in Oncology 23:2, 177-182
CrossRef246
Julian Downward. (2011) Targeting RAF: trials and tribulations. Nature Medicine 17:3, 286-288
CrossRef247
Jan P Deroose, Alexander MM Eggermont, Albertus N van Geel, Cornelis Verhoef. (2011) Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha. Current Opinion in Oncology 23:2, 183-188
CrossRef248
Peter E Schwartz. (2011) Germ cell tumors of the ovary. Expert Review of Obstetrics & Gynecology 6:2, 163-178
CrossRef249
Solit, David B., Rosen, Neal, . (2011) Resistance to BRAF Inhibition in Melanomas. New England Journal of Medicine 364:8, 772-774
Full Text250
Eric D. Green, Mark S. Guyer, Eric D. Green, Mark S. Guyer, Teri A. Manolio, Jane L. Peterson. (2011) Charting a course for genomic medicine from base pairs to bedside. Nature 470:7333, 204-213
CrossRef251
Miller, Franklin G., Joffe, Steven, . (2011) Equipoise and the Dilemma of Randomized Clinical Trials. New England Journal of Medicine 364:5, 476-480
Full Text252
Colin R Lindsay, Jim Cassidy. (2011) XELOX in colorectal cancer: a convenient option for the future?. Expert Review of Gastroenterology & Hepatology 5:1, 9-19
CrossRef253
Ragini Kudchadkar, Vernon Sondak. (2011) Adjuvant interferon: recommit or move on?. The Lancet Oncology 12:2, 112-113
CrossRef254
Andrew X. Zhu, Aram F. Hezel. (2011) Development of molecularly targeted therapies in biliary tract cancers: Reassessing the challenges and opportunities. Hepatology 53:2, 695-704
CrossRef255
J Lin, Y Goto, H Murata, K Sakaizawa, A Uchiyama, T Saida, M Takata. (2011) Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. British Journal of Cancer 104:3, 464-468
CrossRef256
John M. Kirkwood. (2011) New and More Facile Endpoints in Oncology. Health Outcomes Research in Medicine 2:1, e1-e2
CrossRef257
Devarati Mitra, Kathleen C. Robinson, David E. Fisher. (2011) Melanoma and viagra: an unexpected connection. Pigment Cell & Melanoma Research 24:1, 16-18
CrossRef258
Keith T. Flaherty. (2011) Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress. Pigment Cell & Melanoma Research 24:1, 107-109
CrossRef259
H-T Arkenau, R Kefford, G V Long. (2011) Targeting BRAF for patients with melanoma. British Journal of Cancer 104:3, 392-398
CrossRef260
Feero, W. Gregory, Guttmacher, Alan E., , McDermott, Ultan, Downing, James R., Stratton, Michael R., . (2011) Genomics and the Continuum of Cancer Care. New England Journal of Medicine 364:4, 340-350
Full Text261
F Kern, T Niault, M Baccarini. (2011) Ras and Raf pathways in epidermis development and carcinogenesis. British Journal of Cancer 104:2, 229-234
CrossRef262
Ryan J. Sullivan, Keith T. Flaherty. (2011) BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance. Journal of Skin Cancer 2011, 1-8
CrossRef263
Paolo A Ascierto, Francesco M Marincola. (2011) Combination therapy: the next opportunity and challenge of medicine. Journal of Translational Medicine 9:1, 115
CrossRef264
Hidde M. Kroon. (2011) Treatment of Locally Advanced Melanoma by Isolated Limb Infusion with Cytotoxic Drugs. Journal of Skin Cancer 2011, 1-7
CrossRef265
Efsevia Vakiani, David B Solit. (2011) KRAS and BRAF: drug targets and predictive biomarkers. The Journal of Pathology 223:2, 220-230
CrossRef266
Yassir Sbitti, Zouhour Fadoukhair, Habiba Kadiri, Mohamed Oukabli, Ismail Essaidi, Saoussan Kharmoum, Hind M'rabti, Abderrahmane Albouzidi, Mohammed Ichou, Hassan Errihani. (2011) Diagnostic challenge for ovarian malignant melanoma in premenopausal women: Primary or metastatic?. World Journal of Surgical Oncology 9:1, 65
CrossRef267
Efisio Puxeddu, Serena Romagnoli, Massimo Eugenio Dottorini. (2011) Targeted therapies for advanced thyroid cancer. Current Opinion in Oncology 23:1, 13-21
CrossRef268
R Matthew Klein, Paul J Higgins. (2011) A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition. Molecular Cancer 10:1, 114
CrossRef269
Andrew G. Gianoukakis, Silvana M. Giannelli, Wael A. Salameh, Laron W. McPhaul. (2011) Well differentiated follicular thyroid neoplasia: Impact of molecular and technological advances on detection, monitoring and treatment. Molecular and Cellular Endocrinology 332:1-2, 9-20
CrossRef270
Ignacio Garrido-Laguna, Filip Janku, Christos Vaklavas, Gerald S. Falchook, Siqing Fu, David S. Hong, Aung Naing, Apostolia M. Tsimberidou, Sijin Wen, Razelle Kurzrock. (2011) Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. Cancern/a-n/a
CrossRef271
Ryo Tanaka, Kazuo Koyanagi, Norihiko Narita, Christine Kuo, Dave S.B. Hoon. (2011) Prognostic molecular biomarkers for cutaneous malignant melanoma. Journal of Surgical Oncologyn/a-n/a
CrossRef272
Gustavo Baretton, Stephan Grabbe, Ulrich Keilholz, Guido Sauter. (2011) Molekulare Diagnostik und Therapie in der Onkologie. Onkologie 34:s2, 5-9
CrossRef273
Joanna Xing, Ruixin Liu, Mingzhao Xing, Barry Trink. (2011) The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). Biochemical and Biophysical Research Communications 404:4, 958-962
CrossRef274
Elif Hindié, Farid Sarandi, Soraya Banayan, David Groheux, Domenico Rubello, Laetitia Vercellino, Marie-Elisabeth Toubert, Jean-Luc Moretti, Céleste Lebbé. (2011) Nuclear Medicine in Early-Stage Melanoma: Sentinel Node Biopsy—FDG-PET/CT. PET Clinics 6:1, 9-25
CrossRef275
Shannon R. Bales, Inder J. Chopra. (2011) Targeted Treatment of Differentiated and Medullary Thyroid Cancer. Journal of Thyroid Research 2011, 1-11
CrossRef276
Marc Ladanyi, Pancras CW Hogendoorn. (2011) Cancer biology and genomics: translating discoveries, transforming pathology. The Journal of Pathology 223:2, 99-101
CrossRef277
Paolo A Ascierto, Eleonora De Maio, Stefano Bertuzzi, Giuseppe Palmieri, Ruth Halaban, Mary Hendrix, Mohamed Kashani-sabet, Soldano Ferrone, Ena Wang, Alistair Cochran, Licia Rivoltini, Peter P Lee, Bernard A Fox, John M Kirkwood, Claudio Ullmann, Frederic F Lehmann, Mario Sznol, Douglas J Schwartzentruber, Michele Maio, Keith Flaherty, Jerome Galon, Antoni Ribas, James Yang, David F Stroncek, Nicola Mozzillo, Franco M Marincola. (2011) Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7 th2010". Journal of Translational Medicine 9:1, 32
CrossRef278
Frédéric Pin, Frédéric Buron, Fabienne Saab, Lionel Colliandre, Stéphane Bourg, Françoise Schoentgen, Remy Le Guevel, Christiane Guillouzo, Sylvain Routier. (2011) Synthesis and biological evaluation of 2,3-bis(het)aryl-4-azaindole derivatives as protein kinase inhibitors. MedChemComm 2:9, 899
CrossRef279
Selma Ugurel. (2011) Chemotherapy in Metastatic Melanoma – Still Useful or Out of Date?. Onkologie 34:4, 159-160
CrossRef280
Daniela Göppner, Martin Leverkus. (2011) Prognostic Parameters for the Primary Care of Melanoma Patients: What Is Really Risky in Melanoma?. Journal of Skin Cancer 2011, 1-13
CrossRef281
Keith T. Flaherty. (2011) BRAF Inhibitors and Melanoma. The Cancer Journal 17:6, 505-511
CrossRef282
Russ B. Altman, Heyo K. Kroemer, Catherine A. McCarty, Mark J. Ratain, Dan Roden. (2011) Pharmacogenomics: will the promise be fulfilled?. Nature Reviews Genetics 12:1, 69-73
CrossRef283
Montserrat Blanco Codesido, Andre Tesainer Brunetto, Sophia Frentzas, Victor Moreno Garcia, Dionysis Papadatos-Pastos, Joanna Vitfell Pedersen, Leonardo Trani, Martina Puglisi, L. Rhoda Molife, Udai Banerji. (2011) Outcomes of Patients with Metastatic Melanoma Treated with Molecularly Targeted Agents in Phase I Clinical Trials. Oncology 81:2, 135-140
CrossRef284
Kim Hookim, Michael H. Roh, Joseph Willman, Jeremiah Placido, Helmut C. Weigelin, Kristina L. Fields, Judy Pang, Bryan L. Betz, Stewart M. Knoepp. (2011) Application of immunocytochemistry and BRAF mutational analysis to direct smears of metastatic melanoma. Cancer Cytopathologyn/a-n/a
CrossRef285
Christopher A. Klebanoff, Nicolas Acquavella, Zhiya Yu, Nicholas P. Restifo. (2011) Therapeutic cancer vaccines: are we there yet?. Immunological Reviews 239:1, 27-44
CrossRef286
F. Pandolfi, R. Cianci, D. Pagliari, F. Casciano, C. Bagalà, A. Astone, R. Landolfi, C. Barone. (2011) The Immune Response to Tumors as a Tool toward Immunotherapy. Clinical and Developmental Immunology 2011, 1-12
CrossRef287
Barry S. Taylor, Marc Ladanyi. (2011) Clinical cancer genomics: how soon is now?. The Journal of Pathology 223:2, 319-327
CrossRef288
Franziska Niehr, Erika von Euw, Narsis Attar, Deliang Guo, Doug Matsunaga, Hooman Sazegar, Charles Ng, John A Glaspy, Juan A Recio, Roger S Lo, Paul S Mischel, Begonya Comin-Anduix, Antoni Ribas. (2011) Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. Journal of Translational Medicine 9:1, 76
CrossRef289
E. Elizabeth Patton, Marie E. Mathers, Manfred Schartl. 2011. Generating and Analyzing Fish Models of Melanoma. , 339-366.
CrossRef290
Daniela Gonsalves Shapiro, Wolfram E. Samlowski. (2011) Management of Melanoma Brain Metastases in the Era of Targeted Therapy. Journal of Skin Cancer 2011, 1-6
CrossRef291
Christopher Zito, Harriet M. Kluger. (2011) Immunotherapy for metastatic melanoma. Journal of Cellular Biochemistryn/a-n/a
CrossRef292
Nagashree Seetharamu, Ting J. Tu, Paul Christos, Patrick A. Ott, Russell S. Berman, Richard L. Shapiro, Iman Osman, Anna C. Pavlick. (2011) Enrollment in Clinical Trials Correlates with Improved Survival in Metastatic Melanoma. Oncology 81:5-6, 403-409
CrossRef293
Ramin Nazarian, Hubing Shi, Qi Wang, Xiangju Kong, Richard C. Koya, Hane Lee, Zugen Chen, Mi-Kyung Lee, Narsis Attar, Hooman Sazegar, Thinle Chodon, Stanley F. Nelson, Grant McArthur, Jeffrey A. Sosman, Antoni Ribas, Roger S. Lo. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:7326, 973-977
CrossRef294
Cory M. Johannessen, Jesse S. Boehm, So Young Kim, Sapana R. Thomas, Leslie Wardwell, Laura A. Johnson, Caroline M. Emery, Nicolas Stransky, Alexandria P. Cogdill, Jordi Barretina, Giordano Caponigro, Haley Hieronymus, Ryan R. Murray, Kourosh Salehi-Ashtiani, David E. Hill, Marc Vidal, Jean J. Zhao, Xiaoping Yang, Ozan Alkan, Sungjoon Kim, Jennifer L. Harris, Christopher J. Wilson, Vic E. Myer, Peter M. Finan, David E. Root, Thomas M. Roberts, Todd Golub, Keith T. Flaherty, Reinhard Dummer, Barbara L. Weber, William R. Sellers, Robert Schlegel, Jennifer A. Wargo, William C. Hahn, Levi A. Garraway. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:7326, 968-972
CrossRef295
David Solit, Charles L. Sawyers. (2010) Drug discovery: How melanomas bypass new therapy. Nature 468:7326, 902-903
CrossRef296
Michael J. Haas. (2010) Melanoma: three ways around BRAF inhibition. Science-Business eXchange 3:47,
CrossRef297
(2010) Inhibition of Mutated BRAF in Melanoma. New England Journal of Medicine 363:23, 2261-2262
Full Text298
Herlyn, Meenhard, Nathanson, Katherine L., . (2010) Taking the Guesswork Out of Uveal Melanoma. New England Journal of Medicine 363:23, 2256-2257
Full Text299
Farah L. Rehman, Christopher J. Lord, Alan Ashworth. (2010) Synthetic lethal approaches to breast cancer therapy. Nature Reviews Clinical Oncology 7:12, 718-724
CrossRef300
L. Martin. (2010) Quoi de neuf en thérapeutique dermatologique ?. Annales de Dermatologie et de Vénéréologie 137, S165-S176
CrossRef301
Th. Passeron. (2010) Quoi de neuf en recherche dermatologique ?. Annales de Dermatologie et de Vénéréologie 137, S137-S144
CrossRef302
Jessie Villanueva, Adina Vultur, John T. Lee, Rajasekharan Somasundaram, Mizuho Fukunaga-Kalabis, Angela K. Cipolla, Bradley Wubbenhorst, Xiaowei Xu, Phyllis A. Gimotty, Damien Kee, Ademi E. Santiago-Walker, Richard Letrero, Kurt D'Andrea, Anitha Pushparajan, James E. Hayden, Kimberly Dahlman Brown, Sylvie Laquerre, Grant A. McArthur, Jeffrey A. Sosman, Katherine L. Nathanson, Meenhard Herlyn. (2010) Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:6, 683-695
CrossRef303
Roger Mouawad, Jean-Philippe Spano, David Khayat. (2010) Paving the way to the cure of melanoma. Melanoma Research 20:6, 441-442
CrossRef304
Jose Lutzky. (2010) New Therapeutic Options in the Medical Management of Advanced Melanoma. Seminars in Cutaneous Medicine and Surgery 29:4, 249-257
CrossRef305
David Solit, Neal Rosen. (2010) Oncogenic RAF: a brief history of time. Pigment Cell & Melanoma Research 23:6, 760-762
CrossRef306
Jonathan Hall, Patrick Dennler, Stephanie Haller, Anna Pratsinis, Katharina Säuberli, Harry Towbin, Katja Walthe, Janine Woytschak. (2010) Genomics drugs in clinical trials. Nature Reviews Drug Discovery 9:12, 988-988
CrossRef307
John T. Lee, Ling Li, Patricia A. Brafford, Marcia van den Eijnden, Molly B. Halloran, Katrin Sproesser, Nikolas K. Haass, Keiran S.M. Smalley, James Tsai, Gideon Bollag, Meenhard Herlyn. (2010) PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell & Melanoma Research 23:6, 820-827
CrossRef308
L. Mortier. (2010) Quoi de neuf en cancérologie cutanée ?. Annales de Dermatologie et de Vénéréologie 137, S158-S164
CrossRef309
Sigrid M. C. Broekaert, Ritu Roy, Ichiro Okamoto, Joost van den Oord, Jürgen Bauer, Claus Garbe, Raymond L. Barnhill, Klaus J. Busam, Alistair J. Cochran, Martin G. Cook, David E. Elder, Stanley W. McCarthy, Martin C. Mihm, Dirk Schadendorf, Richard A. Scolyer, Alan Spatz, Boris C. Bastian. (2010) Genetic and morphologic features for melanoma classification. Pigment Cell & Melanoma Research 23:6, 763-770
CrossRef310
T.K. Eigentler, F. Meier, U. Keilholz, A. Hauschild, C. Garbe. (2010) Systemische Therapie des metastasierten Melanoms. Der Onkologe 16:12, 1160-1166
CrossRef311
Heidi Ledford. (2010) The roots of resistance. Nature 468:7323, 490-490
CrossRef312
Nicholas P. Restifo. (2010) Can Antitumor Immunity Help to Explain “Oncogene Addiction”?. Cancer Cell 18:5, 403-405
CrossRef313
Alexandra Flemming. (2010) Cancer: Targeting mutant BRAF in metastatic melanoma. Nature Reviews Drug Discovery 9:11, 841-841
CrossRef314
Adina Vultur, Jessie Villanueva, Meenhard Herlyn. (2010) BRAF Inhibitor Unveils Its Potential against Advanced Melanoma. Cancer Cell 18:4, 301-302
CrossRef315
Gideon Bollag, Peter Hirth, James Tsai, Jiazhong Zhang, Prabha N. Ibrahim, Hanna Cho, Wayne Spevak, Chao Zhang, Ying Zhang, Gaston Habets, Elizabeth A. Burton, Bernice Wong, Garson Tsang, Brian L. West, Ben Powell, Rafe Shellooe, Adhirai Marimuthu, Hoa Nguyen, Kam Y. J. Zhang, Dean R. Artis, Joseph Schlessinger, Fei Su, Brian Higgins, Raman Iyer, Kurt D’Andrea, Astrid Koehler, Michael Stumm, Paul S. Lin, Richard J. Lee, Joseph Grippo, Igor Puzanov, Kevin B. Kim, Antoni Ribas, Grant A. McArthur, Jeffrey A. Sosman, Paul B. Chapman, Keith T. Flaherty, Xiaowei Xu, Katherine L. Nathanson, Keith Nolop. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:7315, 596-599
CrossRef316
(2010) Hope in translation. Nature 467:7315, 499-499
CrossRef317
J. S. de Bono, Alan Ashworth. (2010) Translating cancer research into targeted therapeutics. Nature 467:7315, 543-549
CrossRef318
Heidi Ledford. (2010) Rare victory in fight against melanoma. Nature 467:7312, 140-141
CrossRef319
(2010) Cancer biology: Targeting skin tumours. Nature 467:7311, 8-8
CrossRef320
Igor Puzanov, Keith T. Flaherty. (2010) Targeted Molecular Therapy in Melanoma. Seminars in Cutaneous Medicine and Surgery 29:3, 196-201
CrossRef321
Smalley, Keiran S.M., Sondak, Vernon K., . (2010) Melanoma — An Unlikely Poster Child for Personalized Cancer Therapy. New England Journal of Medicine 363:9, 876-878
Full Text
- Letters
